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 Inhibiting STAT3 dimerization and the interaction of STAT3 with the DNA-binding 
domain is important for preventing the progression of malignant transformations in glioma, 
breast, prostate, ovarian and other cancers. The Tius group has designed STAT3 inhibitors that 
disrupt STAT3 dimerization/DNA-binding. However, for these STAT3 inhibitors to be 
developed into effective anti-cancer drugs, the potency and physicochemical properties of these 
molecules needs to be improved.  
 Previous SAR analysis was performed to improve the potency and physicochemical 
properties of the STAT3 inhibitors and from this analysis a general scaffold was developed 
(Chapter 1, Figure 7). It was determined that pyridine or pyrazine structural motifs in region 2 
(R2) produced the most potent compounds compared to analogs with different heterocycles. To 
resolve which heteroarene, pyridine or pyrazine, produces the most potent compounds more 
analogs containing these functional groups were needed for comparison. It was also shown that 
one compound with difluorocyanobenzenesulfonamide in region 3 (R3) had improved potency 
over its pentafluorobenzenesulfonamide analog. To confirm that the 
difluorocyanobenzenesulfonamide fragment generally improves compound potency, more 
analogs needed to be examined. Furthermore, it was discovered that compounds containing a 
carboxyl or hydroxamic acid functional group in region 4 (R4) have good potency, but poor 
permeability. Functionalities in R4 needed to be varied to improve both potency and 
permeability.  
 In an attempt to optimize R2, R3, and R4 in terms of potency and physicochemical 






and synthesized using convergent routes containing 7-15 synthetic steps. The synthetic route 
employed had broad functional group tolerance that easily enabled the development of a small 
molecule library for biological screening. Each molecule prepared was tested for STAT3 DNA-
binding inhibitory activity using the EMSA assay. The physicochemical properties of lead 
inhibitory agents will be tested in the near future. 
 SAR analysis on R2 was inconclusive; more analogs comparing pyridine and pyrazine 
need to be explored to resolve which heterocycle leads to the most potent compounds. Replacing 
the pentafluorobenzenesulfonamide functional group with difluorocyanobenzenesulfonamide 
increased potency in three out of the four analog comparisons suggesting that compounds with 
R3 = difluorocyanobenzenesulfonamide have better potency compared to analogs with R3 = 
pentafluorobenzenesulfonamide. Compounds with R4 = N-methylsalicylamide, N,N-
dimethylsalicylamide, meta-difluoromethylbenzene, or meta-fluorobenzene had similar or lower 
STAT3 inhibitory activity than the parent compounds with R4 = salicylic acid. However, 
replacing the salicylic acid functionality with benzene enhanced potency. This suggests that 
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The signal transducer and activator of transcription (STAT) proteins are a family of 
proteins that are activated by cytokine and growth factor responses.1,2 Activation of STAT 
proteins by cytokines and growth factors promote cell growth, differentiation, and varying 
immune responses.1,2 There are seven identified STAT family members: STAT1, 2, 3, 4, 5A, 5B, 
and 6. All of the STAT proteins contain common structural domains: N-terminal (ND), coiled-
coil (CCD), DNA binding (DBD), Src homology 2 (SH2), and a transactivation domain (TAD) 
which contains a critical Tyrosine (Y) residue (Figure 1).3 
 
 
Figure 1: Diagram of the Structural Domains of the STAT3 Protein3 
 
Note: Sites A-B are sites where STAT3 inhibitors can interact with the STAT3 protein. 
 
 
 Each protein contains a tyrosine residue in the TAD domain at the C-terminus which is 
phosphorylated during activation.3 STAT activation is induced by phosphorylation which is 
controlled by growth factor tyrosine kinases, cytoplasmic kinases, cytokine receptor-associated 
Janus kinases (JAKs), and Src family kinases (Site A, Figure 2).3 Once STAT proteins are 
phosphorylated, dimer formation is stimulated between two STAT monomers (Site B, Figure 2). 
The STAT: STAT dimer is formed through a reciprocal phosphorylated tyrosine Y-SH2 domain 
interaction (Figure 1).3 The STAT: STAT dimer is translocated to the nucleus where it binds 









            Figure 2: Diagram of the STAT3 Signaling Pathway3 
 
STAT activation in normal cells only persists for a short time period. However, aberrant 
activation of STAT3 occurs in cancerous transformations and has been shown to be associated 
with glioma, breast, prostate, and other cancers.3-6 STAT3 induces tumorigenesis by 
dysregulating gene expression which leads to uncontrolled tumor growth and represses tumor 
immune surveillance.1,4-10 Thus, STAT3 is an enticing target for the discovery of anticancer 
drugs.6  
Currently, the most promising way of disrupting the STAT3 signaling pathway is by 
inhibiting the dimerization step (Site B, Figures 1 & 2) with STAT3 inhibitors.5, 11-18 The first 
promising STAT3 dimerization inhibitor discovered by Turkson and Gunning was BP-1-102 (A, 






Computational modeling predicted that BP-1-102 binds to three sub-pockets of the STAT3-
STAT3 dimer interface, with the pentafluorobenzenesulfonamide moiety projecting into the  
third sub-pocket composed of Lys591, Glu594, Ile634, and Arg595 (B, Figure 3).13 BP-1-102 
was also shown to inhibit STAT3 DNA-binding activity in vitro with an IC50 = 6.8 ± 0.8 µM as 
measured by the electrophoretic mobility shift assay (EMSA).13 Moreover, BP-1-102 inhibited 
growth of mouse xenografts of human breast (MDA MB-231) and lung (A549) tumors that 





Figure 3. Structure of BP-1-102 (A) and Computational Model of BP-1-102 Interacting 
with the STAT3 SH2 Domain (B)13 
 
Note: (B, Left) STAT3 monomer: solvent accessible surface of the SH2 domain (off-white), hydrophobic residues 
(pink), hydrophilic residues (blue), and BP-1-102 (cyan). (B, Right) BP-1-102 accessing the three sub-pockets of the 













Figure 4. Antitumor Effects of Bp-1-102 in Human Breast (A, B) and Lung (C) Tumor 
Xenografts13 
 
Note: Mice with MDA-MB-231 (A, B) or A549 (C) tumors were given BP-1-102 via i.v., 1-3 mg/kg or control 




SH5-07 and SH4-54 were the second and third lead STAT3 inhibitors that emerged from 
the collaboration between the Tius and Turkson groups and they are analogs of BP-1-102 
(Figure 5). SH5-07 and SH4-54 showed improved inhibition of STAT3 DNA-binding with 
EMSA IC50 = 3.9 ± 0.6 µM and 4.7 ± 0.5 µM, respectively, compared to BP-1-102 (IC50 = 6.8 ± 
0.8 µM) (A, Figure 5).6 The improved potency of SH5-07 and SH4-54 suggests that the 
hydroxyl functionality in the salicylic acid moiety of BP-1-102 may not be necessary. NMR 
experiments showed that SH4-54 interacts with the SH2 and DB domains and that SH4-54 is 
likely interacting with the DBD by alkylating a cysteine residue.6 Furthermore, EMSA analysis 
showed that transiently expressed STAT3 SH2 domain rescued STAT3 activity from SH4-54 
compared with moderate rescue by the DBD domain (B, Figure 5).6 This suggests that the small 
molecule inhibitors SH4-54 and SH5-07 interact with both domains. Similar to BP-1-102, SH5-
07 and SH4-54 inhibited the growth of human breast (MDA-MB-231) and glioma (U251MG) 







No significant changes in body weight, blood cell counts, or signs of toxicity were observed in 
mice.6 Altogether these results indicate that SH5-07 and SH4-54 have potential as anti-cancer 
drugs.  
 
Figure 5. Structures of SH5-07 and SH4-54 (A) and STAT3 DNA-Binding EMSA 
Analysis of Nuclear Extracts from U251MG Cells Overexpressing STAT3 SH2 or 
DB Domain That Were Treated with SH4-546 
 





Figure 6. Antitumor Effects of SH5-07 and SH4-54 in Human Glioma U251MG (A) 
and Breast MDA-MB-231 Tumor Xenografts6 
 
Note: (A) and (B) left plots are from intravenous administration of SH5-07 and SH4-54 (5 or 6 mg/kg 








Extensive structure-activity relationship (SAR) analysis on BP-1-102, SH5-07, and SH4-
54 was performed to improve the potency and physicochemical properties. This analysis led to 
the formation of a general scaffold for the STAT3 inhibitors (Figure 7). In an attempt to increase 
the potency of the lead compounds (BP-1-102, SH4-57, and SH5-07) the cyclohexane 
functionality was substituted with heterocycles. Replacing the cyclohexane moiety with 
tetrahydro-4H-pyran (S3I-H003, S3I-H005, and S3I-H006) or piperidine (S3I-H020 and S3I-
H039) decreased the activity compared to the parent analogs, BP-1-102, SH4-54, and SH5-07 
(Table 1).19 Replacing the cyclohexane group with 4,4-difluorocyclohexane (S3I-H014) or 
cycloheptane (S3I-H040) resulted in diminished STAT3 inhibitory activity (Table 1).19 These 
results show that the most potent compounds are those which contain a cyclohexane 




Figure 7. General Scaffold for STAT3 Inhibitors 
 
Note: R2 (X1/X2 = N or CH), R4 (X3 = OH, NHOH, H, etc., X4 = H, OH, ONa, CH2COOH, etc., X3 to X4 = 
















SAR analysis revealed that when the functionality in R2 is changed from phenyl (S3I-
H098) to pyridine (S3I-H127) the potency is enhanced (IC50 = 0.546 ± 0.014 µM vs. 0.384 ± 
0.024 µM) (Figure 7, Figure 8). Pyrimidine S3I-H143 (IC50 = 0.497 µM) and pyridazine S3I-
H144 (IC50 = 0.721 µM) decreased activity compared to the parent pyridine analog S3I-H127 
(IC50 = 0.384 ± 0.024 µM). Recent SAR analysis has shown that when pyridine is replaced with 






This is evident when comparing S3I-H127 with S3I-H142, IC50 = 0.384 ± 0.024 µM vs. 0.42 
µM (Figure 8). These results indicate that more analogs comparing pyridine and pyrazine need 
to be explored to determine which functionality is optimal for R2.  
 
 
Figure 8. Structures of S3I-H098, S3I-H127, S3I-H142, S3I-H143, and S3I-H144 
 
Substitution of glycine in BP-1-102 (IC50 = 6.8 ± 0.8 µM) with (R)-alanine in the linker 
region to form S3I-H012 (IC50 = 3.0 ± 0.9 µM) led to improved activity in disrupting STAT3 
DNA-binding in vitro (Figure 9).19 However, the (S)-alanine analog S3I-H011 (IC50 = 5.0 ± 0.2 
µM) had lower activity (Figure 9).19 Unfortunately, it was found that alanine based compounds 
have lower metabolic stability compared to glycine based compounds. For example, S3I-H048, 
Mouse Liver Microsomes (MLM)/Human Liver Microsomes (HLM) half-life (t1/2) £ 5 min vs. 
SH4-54 and SH5-07 MLM/HLM t1/2 ³ 17 min (Table 2).19 This suggests that the alanine 






With the hope of improving metabolic stability while maintaining potency, proline linker 
compounds were designed and prepared. When the linker was changed from (R)-alanine to (R)-
proline to form S3I-H070 (IC50 = 2.4 ± 0.2 µM), potency was enhanced.19 Like the (S)-alanine 
analog the (S)-proline analog S3I-H069 (IC50 = 7.2 ± 3.4 µM) of S3I-H070 showed diminished 
activity (Figure 9).19 Satisfyingly, it was found that proline based analog S3I-H089 had 
improved microsomal metabolic stability over S3I-H048, MLM/HLM t1/2 = 18 and 15 min vs. 
MLM/HLM t1/2 £ 5 min (Table 2).19 When the linker was changed from (R)-proline to (R)-
azetidine to form S3I-H098 (IC50 = 0.546 ± 0.014 µM) the inhibition activity was enhanced even 
further (Figure 9).19 The metabolic stability of azetidine containing compounds is currently 
being tested. These results show that the most potent compounds are currently those which have 
azetidine in the linker region (Figure 7). 
 
 

















 It was determined that when the number of fluorine atoms is decreased in varying ways 
on the aromatic ring in R3 STAT3 DNA-binding inhibition is significantly reduced when 
compared to the parent compound, BP-1-102 vs. S3I-H001, S3I-H007, and S3I-H101 (Table 
3).19 Additionally, when the pentafluorophenyl group is replaced with 3,5-
bis(trifluoromethyl)phenyl (S3I-H009) or pyridyl (S3I-H002) activity was reduced substantially 
(Table 3).19 Replacing the pentafluorobenzenesulfonamide with pentafluorobenzamide (S3I-
H086) or pentafluorobenzylamine (S3I-H087) was not tolerated and reduced inhibitory activity 







S3I-H142 (IC50 = 0.42 µM) is replaced with difluorocyanobenzenesulfonamide to form S3I-
H203 (IC50 = 0.283 ± 0.031 µM), a slight increase in STAT3 DNA-binding inhibition is 
observed (Figure 10).19 These results indicate that more analogs bearing the 
pentafluorobenzenesulfonamide and difluorocyanobenzenesulfonamide functionalities in R3 need 
to be compared to confirm that compounds with difluorocyanobenzenesulfonamide are more 
potent (Figure 7). 
 










Figure 10. Structures of S3I-H142 and S3I-H203 
 
 
 To improve the potency of the lead compounds SH5-07 and SH4-54, region 4 (R4) was 
modified with various functional groups (Figure 7). Replacing the aromatic system with 
heterocycles such as pyridine or oxazole (S3I-H019 or S3I-H030) reduced STAT3 DNA-
binding inhibitory activity compared to the parent compounds, SH5-07 and SH4-54 (Table 4).19 
Additionally, it was found that replacing the 4-substituted benzoic acid moiety with 3-substituted 
phenylacetic acid (S3I-H008) significantly reduced the inhibitory activity (Table 4).19 Likewise, 
isoindolinone and indazole (S3I-H033 and S3I-H043) had weaker inhibitory activity compared 
to the parent compounds, S3I-H015 and S3I-H017 (Table 4).19 Together, this data suggests that 
the carboxyl group in R4 can only be replaced by the hydroxamic acid moiety for STAT3 
inhibitory activity to be maintained (Figure 7). 
 The sodium benzoate analog (S3I-H048) had decreased inhibitory activity compared to 
the parent compound, S3I-H012 (Table 4).19 As predicted, S3I-H048 had better solubility in pH 
7.4 phosphate-buffered saline (PBS) and pH 6.8 buffered simulated intestinal fluid (SIF)  








It was shown that SH4-54, SH5-07, and the sodium benzoate analog, S3I-H048, were 
impermeable by the Caco-2-cell permeability assay (Table 5).19 The Caco-2 cell line is derived 
from human colon carcinoma and these cells are used to model the human intestinal absorption 
of drugs.29 Caco-2-cells are grown on a semi-permeable plastic support which is fitted into a 
multi-well plate and compounds are added to the apical (cells of the monolayer facing the lumen) 
or basolateral (cells of the monolayer not facing the lumen) sides of the monolayer and the flux 
from apical to basolateral or vice versa is measured.29 Compounds with good permeability need 
to have an apical to basolateral efflux > 0.9 x 10-6 cm/s.24 These results indicate that functional 
groups that contain a carboxyl or hydroxamic acid moiety in R4 have good potency but poor 
permeability (Figure 7). Functionalities in this region need to be varied to improve permeability 
without compromising potency.  







Table 5. Structure, Solubility, and Permeability of SH4-54, SH5-07, and S3I-H04819 
 
 
 The research goals of this thesis were to optimize R2, R3, and R4 in terms of potency as 
well as physicochemical properties (Figure 7). The design of the targets whose structures are 
shown in Figure 11 was based on the SAR analysis of the lead STAT3 inhibitory agents as 
previously discussed. Each target was designed, synthesized, characterized, and subsequently 
tested for STAT3 DNA-binding inhibitory activity using the EMSA IC50 assay at the UH Cancer 
Center. The physicochemical properties of lead inhibitory agents will be tested in the near future. 
The synthesis of each compound in Figure 11 will be discussed in detail in Chapter 2.   
To determine which functionality, pyridine or pyrazine, is the most potent group for R2, 
targets S3I-H204, S3I-H222, S3I-H230, S3I-H235, S3I-H233, S3I-H244, and S3I-H245 were 






S3I-212, S3I-H224, S3I-H230, S3I-H228, S3I-H237, S3I-H239, and S3I-H244 were compared 
to their difluorocyanobenzenesulfonamide or pentafluorobenzenesulfonamide analogs to 
determine which functionality is optimal in R3 (Figure 7, Figure 11). Various functionalities on 
the aromatic ring in R4 were examined in hopes of increasing the potency, metabolic stability, 
and cellular permeability (Figure 7, Figure 11).   
 


















































2.1 Proposed Synthetic Routes for the Targeted STAT3 Inhibitors  
 
 All of the targeted STAT3 inhibitors shown in Figure 11 are based on the azetidinamide 
scaffold and have two amine groups condensed with three different functionalities. It was 
envisioned that each target could be synthesized using common synthetic routes developed by 
our group, and derivatized further if necessary.19, 22 Our group has developed a convergent 
synthesis of our core scaffolds, in which 3, 17, and 20 are made in bulk (Scheme 1, Scheme 2).  
 The synthesis of N-((5-cyclohexylpyridin-2-yl)methyl)aniline 7 and N-((5-
cyclohexylpyrazin-2-yl)methyl)aniline 8 precursors could proceed by previously developed 
synthetic routes A and B (Scheme 1).22 Using route A, aniline 1 can easily be converted to its 
trifluoroacetamide derivative 2 using TFAA and pyridine (route A; reaction a).23 A SN2 reaction 
with catalytic iodide can be used to convert trifluoroacetamide 2 to its N-((5-cyclohexylpyridin-
2-yl)methyl)trifluoroacetamide 5 and N-((5-cyclohexylpyrazin-2-yl)methyl)trifluoroacetamide 6 
derivatives (route A; reactions b and c).22 Subsequent deprotection of 5 or 6 with potassium 
carbonate in MeOH/THF will yield the desired N-((5-cyclohexylpyridin-2-yl)methyl)aniline 7 
and N-((5-cyclohexylpyrazin-2-yl)methyl)aniline 8 precursors (route A; reaction d).25  
 Alternatively, the synthesis of N-((5-cyclohexylpyridin-2-yl)methyl)aniline 7 and N-((5-
cyclohexylpyrazin-2-yl)methyl)aniline 8 precursors could proceed by synthetic route B (route B; 
Scheme 1). Using Buchwald-Hartwig amidation conditions, bromobenzene 9 can be transformed 
into its tert-butyl carbamate derivative 10 (route B; reaction e).26 Reacting carbamate 10 with 2-
(chloromethyl)-5-cyclohexylpyridine 3 or (5-cyclohexylpyrazin-2-yl)methyl methanesulfonate 4 
using typical SN2 reaction conditions should provide carbamates 11 or 12 (route B; reactions f 
and g).22 Deprotection of 11 and 12 with TFA should yield the desired aniline precursors 7 and 8 









Scheme 1: Proposed Synthetic Routes A and B for the Synthesis of N-((5-cyclohexylpyridin-2-
yl)methyl)aniline 7 and N-((5-cyclohexylpyrazin-2-yl)methyl)aniline 8a 
 
aReagents and Conditions: Route A – (a) TFAA, pyridine, DCM, 0 to 25 °C; (b) 3, NaI (cat.), K2CO3, ACN, 65 °C; 
(c) 4, NaI, K2CO3, ACN, 60 °C; (d) K2CO3, THF/MeOH, 25 °C; Route B – (e) t-butyl carbamate, Pd(OAc)2, 
Xantphos, Cs2CO3, dioxane, 100 °C; (f) 3, KHMDS, DMF, 0 to 25 °C; (g) 4, KHMDS, DMF, 0 to 25 °C; (h) TFA, 




 For the synthesis of the targets (S3I-H204, S3I-H212, 41, S3I-H222, S3I-H230, S3I-
H235, S3I-H237, S3I-H244, and S3I-H245) in which R3 is difluorocyanobenzenesulfonamide, 
synthetic route C will be utilized (Figure 7, Figure 11, Scheme 2). Anilines 7 and 8 can be 
converted to their anilide derivatives 13 and 14 using MeMgBr and (R)-tert-butyl-2-
(chlorocarbonyl)azetidine-1-carboxylate (route C; reaction i, Scheme 2).22 Azetidine 






Subsequent reaction of amines 15 and 16 with 3-cyano-4,5-difluorobenzene-1-sulfonyl chloride 
17 will yield the pyridine and pyrazine core scaffolds 18 and 19 for the synthetic targets (route 
C; reaction k).22 For the synthesis of targets (S3I-H224, S3I-H233, S3I-H228, and S3I-H239) 
containing the pentafluorobenzenesulfonamide functionality in R3  it was imagined that synthetic 
route D could be used (Figure 7, Figure 11, Scheme 2). Reaction of anilines 7 and 8 with 20 
using MeMgBr will yield the pyridine and pyrazine scaffolds 21 and 22, respectively, for the 
synthetic targets (route D; reaction l, Scheme 2).22 
 
 
Scheme 2: Proposed Synthetic Routes C and D for the Synthesis of the 
Difluorocyanobenzenesulfonamide Core Scaffolds (18 and 19) and the 
Pentafluorobenzenesulfonamide Core Scaffolds (21 and 22)a 
 
aReagents and Conditions: Route C – (i) MeMgBr, (R)-tert-butyl-2-(chlorocarbonyl)azetidine-1-carboxylate, THF, 






2.2 Synthesis of S3I-H204 
 
 For the synthesis of S3I-H204 synthetic routes A (Scheme 1) and C (Scheme 2) were 
utilized. Synthesis of S3I-H204 commenced with the synthesis of 3 at the gram scale (Scheme 
3). Synthetic route A, a synthetic route developed by previous group members, was first 
attempted to synthesize 3.22 However, the conversion of 23 to 24 using standard Suzuki reaction 
conditions produced 24 in low yield, 45% (route A; reaction a).22 The poor yield of this reaction 
may be because 23 is chelating the palladium catalyst thereby inhibiting cross-coupling. 
Subsequent reduction of 24 to 25 and conversion of 25 to alkyl chloride 3 proceeded efficiently 
and duplicated previously reported yields by the group (route A; reactions b and c).22  
 In an attempt to increase the yield of the Suzuki cross-coupling reaction, synthetic route 
B was developed (route B, Scheme 3). Satisfyingly, 26 was converted to 27 in good yield, 82%, 
using standard Suzuki cross-coupling conditions (route B; reaction d). A higher yield was 
obtained in the Suzuki reaction with the pyridyl ester 26 compared to the pyridyl alcohol 23 
because chelation of Pd0 by the pyridyl ester is less efficient than by the pyridyl alcohol. 
Reduction of 27 using Adams’ catalyst in the presence of hydrogen gas gave 28 in excellent 
yield, 96% (route B; reaction e).22 Reduction of ester 28 to form (5-cyclohexylpyridin-2-yl) 
methanol 25 was accomplished using NaBH4 and NaOMe in 80% yield (route B; reaction f).30 
The purpose of NaOMe in this reaction is to stabilize NaBH4 in methanol and it is postulated that 
NaBH3OMe is the active reducing agent.30 Subsequent reaction of 25 with thionyl chloride gave 











Scheme 3: Synthetic Routes A and B for the Synthesis of 2-(chloromethyl)-5-cyclohexylpyridine 
3a 
 
aReagents and Conditions: Route A - (a) Pd(OAc)2 (0.5 eq), SPhos (0.1 eq), cyclohex-1-en-1-yl boronic acid (3.0 
eq), K3PO4 (2.0 eq), HPLC-grade H2O (2.0 eq), THF, 40 °C, 24 h, 45%; (b) PtO2 (0.1 eq), H2 (g), 1:1 
EtOAc/MeOH, 25 °C, 4 h, 94%; (c) SOCl2 (1.5 eq), DCM, 0 to 25 °C, 3 h, quantitative yield; Route B – (d) 
Pd(OAc)2 (0.5 eq), SPhos (1.0 eq), cyclohex-1-en-1-yl boronic acid (2.0 eq), K3PO4 (2.0 eq), HPLC-grade H2O (2.0 
eq), THF, 40 °C, 24 h, 82%; (e) PtO2 (0.1 eq), H2 (g), 1:1 EtOAc/MeOH, 25 °C, 4 h, 96%; (f) NaBH4 (7.0 eq), 
NaOMe (1.1 eq), MeOH, 50 °C, 3 h, 80%. 
 
 The synthetic route to S3I-H204 is outlined in Scheme 4. Reduction of 29 with iron 
powder and ammonium chloride gave amine 30 in 91% yield (reaction a).22, 31 It should be noted 
that reaction (a) is heterogeneous and requires vigorous stirring. Slow stirring of the reaction 
mixture leads to the formation of byproduct 39, which is difficult to separate from 30 using flash 
chromatography (Figure 12). The mechanism for the conversion of 29 to 30 using Fe/NH4Cl 
involves reduction of the nitro group by single electron transfer (SET) from iron. It is unclear 
how byproduct 39 is formed mechanistically due to the lack of literature on the formation of 
hydrazines from nitrobenzenes using iron. Formation of hydrazines from nitroarenes by SET 
from magnesium has been reported and the mechanism is shown in Figure 12.34 Byproduct 39 







Figure 12. Mechanism for the Formation of Hydrazine with Magnesium and Structure of the 
Byproduct from Reaction (a), Scheme 4 
 
Reaction of amine 30 with TFAA and pyridine gave trifluoroacetamide 31 in 84% yield (reaction 
b).22,23 A SN2 reaction in the presence of catalytic NaI was used to convert 31 into 
trifluoroacetamide 32 in 64% yield (reaction c).22 Deprotection of 32 proceeded smoothly with 
K2CO3 giving amine 33 (reaction d).22,25  
 For the synthesis of anilide 36, precursor 35 needed to be synthesized first. Commerically 
available carboxylic acid 34 was converted to acid chloride 35 in quantitative yield using oxalyl 
chloride and catalytic DMF (reaction e).22 Reaction of amine 33 with freshly prepared 35 in the 
presence of MeMgBr produced anilide 36 in 75% yield (reaction f).22 Succesive deprotection of 
36 with TFA gave amine 37 (reaction g).22,28 Reaction of amine 37 with 17 in the presence of 
DIPEA produced sulfonamide 38 in 60% yield over two steps (reaction h).22 Finally, 
deprotection of 38 with 1:1 palladium on carbon/Pd(OH)2 under an atmosphere of hydrogen 
produced S3I-H204 in 50% yield (reaction i).22 It should be noted that in reaction (i), palladium 
is acting as a catalyst, but it is being poisoned. The pyridyl and amine functionalities in 
intermediate 38 are likely interacting with palladium inhibiting turnover. The poor yield in 
reaction (i) can be attributed to the formation of unknown side-products which likely formed 








Scheme 4: Synthesis of S3I-H204a 
 
aReagents and Conditions: (a) Iron powder (7.0 eq), NH4Cl (10.2 eq), 2:1 EtOH/HPLC-grade H2O, 66 °C, 16 h, 
91%; (b) TFAA (1.1 eq), pyridine (2.2 eq), DCM, 0 to 25 °C, 3.5 h, 84%; (c) 3 (1.4 eq), NaI (0.2 eq), K2CO3 (2.0 
eq), ACN, 65 °C, 24 h, 64%; (d) K2CO3 (2.0 eq), 1:1 THF/MeOH, 25 °C, 20 h, 98%; (e) (COCl)2 (1.2 eq), cat. 
DMF, DCM, 25 °C, 1.5 h, quantitative yield; (f) MeMgBr (2.5 eq), 35 (2.1 eq), THF, 0 to 25 °C, 1.2 h, 75%; (g) 
TFA (37 eq), DCM, 25 °C, 1.5 h; (h) 17 (2.0 eq), DIPEA (5.0 eq), DCM, 0 to 25 °C, 2.2 h, 60% (yield over two 
steps); (i) H2 (g), 42 wt% 1:1 Pd/C: Pd(OH)2, 1:1 EtOAc/MeOH, 25 °C, 23 h, 50% 
 
 
2.3 Synthesis of S3I-H212 
 
To synthesize compound S3I-H212, S3I-H204 was derivatized using typical peptide 
coupling conditions (reaction a, Scheme 5).32 Addition of HATU to a solution of S3I-H204 in 
DCM in the presence of DIPEA generated the activated ester which was subsequently reacted 






in a very low yield, 9%. One significant side-product confirmed by 1H NMR and mass 
spectrometry analysis was 40, formed from an SNAr reaction of methylamine with the 
difluorocyanobenzenesulfonamide (Figure 13). Reducing the amount of methylamine in reaction 
(a) will most likely suppress the formation of side-product 40, because methylamine should react 
faster with the activated ester than with difluorocyanobenzene (Figure 13). In the context of 
biological activity, side-product 40 illustrates the importance of the difluorocyanobenzene 
functionality which is labile to attack by cysteine residues in the DNA binding domain of 
STAT3. The SNAr reaction of a cysteine residue with the difluorocyanobenzene functionality is 




Scheme 5: Synthesis of S3I-H212a and the Structure of HATU 
 
aReagents and Conditions: (a) HATU (1.0 eq), DIPEA (1.9 eq), methylamine (1.7 eq), DCM, 0 to 25 °C for 1.5 h 












2.4 Attempts at Synthesizing Compound 41 
 
 In an attempt to synthesize compound 41, S3I-H204 was activated using HATU and 
reacted with dimethylamine in the presence of DIPEA (reaction a, Scheme 6).23 In the hope of 
suppressing the SNAr side product, 42 (Figure 14), a substoichiometric amount of 
dimethylamine was used. Unfortunately, reaction (a) produced many side products as indicated 
by TLC and LCMS. Product 41 was detected by LCMS, but could not be isolated in pure form. 
Reaction (a) in Scheme 6 was not optimized, because S3I-H204 was used up in the initial 
attempt to synthesize 41. Instead an alternative route (Scheme 7) for the synthesis of 41 was 
pursued.  
 
Scheme 6: First Attempt at Synthesizing 41a 
aReagents and Conditions: HATU (1.0 eq), DIPEA (1.9 eq), HN(CH3)2 (0.86 eq), DCM, 0 to 25 °C for 1.5 h then 











The second route that was used in an attempt to synthesize 41 is shown in Scheme 7. The 
attempted synthesis of 41 began by first transforming 43 to its amide derivative 44 using 
standard peptide coupling conditions (reaction a).32 The phenol in intermediate 44 was protected 
using BnBr in the presence of K2CO3 giving 45 in good yield, 84% (reaction b).22 Reduction of 
45 gave aniline 46 and was accomplished using iron powder and NH4Cl as previously discussed 
(reaction c).22, 31 Aniline 46 was reacted with TFAA in the presence of pyridine producing 47 in 
71% yield (reaction d).22,23 A SN2 reaction in the presence of catalytic NaI was used to convert 47 
into trifluoroacetamide 48 (reaction e).22 Deprotection of trifluoroacetamide 48 using K2CO3 
gave amine 49 in 80% yield over two steps (reaction f).22,25 Reacting amine 49 with 35 in the 
presence of MeMgBr produced anilide 50 in 66% yield (reaction g).22 Deprotection of anilide 50 
with TFA gave the trifluoroacetate salt of amine 51 (reaction h).22,28 Reacting 51 with 17 in the 
presence of DIPEA produced sulfonamide 52 in 76% yield over two steps from 50 (reaction i).22 
Unfortunately, deprotection of 52 using 40% by weight Pd/C and 30% by weight 
Pd(OH)2 under a hydrogen atmosphere was problematic (reaction j1). Intermediate 52 was 
consumed completely and product 41 could not be detected by 1H NMR or mass spectrometry. 
Unfortunately, the major product in reaction (j1) could not be determined by 1H NMR analysis. 
A smaller amount of Pd(OH)2 was used in reaction (j2) in the hope of suppressing the formation 
of the unknown compound. Satisfyingly, the desired product 41 was produced as a minor product 
as indicated by LCMS, but could not be isolated. Compound 41 could not be identified by 1H 
NMR due to the large amount of impurities present in the sample. However, LCMS can be used 







Additionally, the major product in reaction (j2) as detected by LCMS was again the unidentified 
compound. These results suggest that Pearlman’s catalyst may be leading to the formation of the 
unidentified compound in reactions (j1) and (j2).        
In reaction (j3), 52 was deprotected using 16% by weight Pd/C in the presence of a 
hydrogen atmosphere. Compound 41 was produced as the major product as indicated by LCMS. 
Unfortunately, 41 could not be isolated in pure form from reaction (j3). Purification by PTLC 
with methanol/ethyl acetate as the eluting solvent led to the formation of an inseparable 
byproduct, 53 (Figure 15). Byproduct 53 was formed from a SNAr reaction on the 
difluorocyanobenzene ring of 41. The effort to optimize the debenzylation reaction was 
abandoned and synthesis of the pyrazine analog (S3I-H222) of 41 was pursued.    
 
Scheme 7: Second Attempt at Synthesizing 41a 
 
aReagents and Conditions: (a) HATU (1.0 eq), DIPEA (0.9 eq), NHMe2 (1.5 eq), DCM, 0 to 25 °C, 26 h, 54%; (b) 
K2CO3 (1.2 eq), BnBr (1.1 eq), DMF, 25 °C, 32 h, 84%; (c) Iron powder (7.0 eq), NH4Cl (10.2 eq), EtOH/HPLC-
grade H2O, 66 °C, 20 h, 87%; (d) TFAA (1.1 eq), pyridine (2.2 eq), DCM, 0 to 25 °C, 1.5 h, 71%; (e) 3 (2.0 eq), 
K2CO3 (2.0 eq), NaI (0.2 eq), ACN, 65 °C, 24 h; (f) K2CO3 (2.0 eq), 1:1 THF/MeOH, 25 °C, 16 h, 80% over two 
steps; (g) MeMgBr (2.5 eq), 35 (2.1 eq), THF, 0 to 25 °C, 1.2 h, 66%; (h) TFA (37 eq), DCM, 25 °C, 1.5 h; (i) 17 
(2.0 eq), DIPEA (6.0 eq), DCM, 0 to 25 °C, 1.7 h, 76% over two steps; (j1) H2 (g), 40 wt% Pd/C, 30 wt%  Pd(OH)2, 
3:1 EtOAc/MeOH, 25 °C, 48 h, 0%; (j2) H2 (g), 12 wt% Pd(OH)2, 1:1 EtOAc/MeOH, 25 °C, 48 h, 0%; (j3) H2 (g), 







Figure 15. Structure of Byproduct 53 from Reaction (j3), Scheme 7 
 
2.5 Synthesis of S3I-H222 
 
 The synthetic route to S3I-H222 is shown in Scheme 8. Commercially available methyl 
5-bromopyrazine-2-carboxylate 54 was coupled with cyclohex-1-en-1-ylboronic acid producing 
55 using standard Suzuki reaction conditions (reaction a).22 Reduction of 55 using PtO2 under a 
hydrogen atmosphere gave 56 in 52% yield (reaction b).22 The poor yield in reaction (b) is due to 
reduction of the pyrazine ring. Reduction of ester 56 using NaBH4 furnished the alcohol 57 in 
good yield, 84% (reaction c).22 Alcohol 57 was transformed into 4 using MsCl in the presence of 
TEA (reaction d).22 
 Due to the instability of compound 4 it was reacted immediately with trifluoroacetamide 
47 using SN2 reaction conditions to give 58 in excellent yield, 97% (reaction e).22 Facile 
deprotection of 58 using K2CO3 in methanol produced 59 in quantitative yield, 99% (reaction 
f).22,25  Anilide 60 was produced by reacting amine 59 with acid chloride 35 in the presence of 
MeMgBr (reaction g).22 Deprotection of anilide 60 produced trifluoroacetate salt 61 (reaction 
h).22,28 Reacting 61 with sulfonyl chloride 17 in the presence of base led to the formation of 
sulfonamide 62 in good yield, 78% over two steps from 60 (reaction i).22 Finally, debenzylation 
of 62 and subsequent purification via PTLC using methanol/ethyl acetate as an eluting solvent 
produced the desired compound S3I-H222 in 44% yield (reaction j).22 The poor yield in reaction 






unreacted 62. It is unclear why S3I-H222 can be isolated using a PTLC purification method with 




Scheme 8: Synthesis of S3I-H222a 
 
aReagents and Conditions: (a) Pd(OAc)2 (0.05 eq), SPhos (0.1 eq), K3PO4 (2.0 eq), cyclohex-1-en-1-ylboronic acid 
(1.5 eq), HPLC-grade H2O (2.0 eq), THF, 40 °C, 22 h, 83%; (b) H2 (g), PtO2 (0.1 eq), 1:1 EtOAc/MeOH, 25 °C, 
20.5 h, 52%; (c) NaBH4 (3.0 eq), MeOH, 0 to 25 °C, 27 min, 84%; (d) MsCl (1.86 eq), TEA (3.0 eq), DCM, 0 °C, 
32 min, 84%; (e) 4 (1.3 eq), K2CO3 (4.0 eq), NaI (0.38 eq), ACN, 60 °C, 14 h, 97%; (f) K2CO3 (2.0 eq), 1:1 
THF/MeOH, 25 °C, 1.5 h, 99%; (g) MeMgBr (2.5 eq), 35 (2.1 eq), THF, 0 to 25 °C, 1.2 h, 75%; (h) TFA (37 eq), 
DCM, 25 °C, 1.5 h; (i) 17 (2.0 eq), DIPEA (8.0 eq), DCM, 0 to 25 °C, 1.7 h, 78% yield over two steps; (j) H2 (g), 20 










2.6. Synthesis of S3I-H224 
 
 For the synthesis of S3I-H224 synthetic routes A (Scheme 1) and D (Scheme 2) were 
utilized. The synthetic route to S3I-H224 is displayed in Scheme 9. Amidation of commercially 
available aniline 63 produced trifluoroacetamide 64 in 87% yield (reaction a).22,23 Exposure of 
trifluoroacetamide 64 to alkyl chloride 3 under SN2 reaction conditions produced 65 in 57% yield 
(reaction b).22 The low yield in reaction (b) is attributed to starting material that was not 
consumed in the reaction. Deprotection of trifluoroacetamide 65 under basic conditions 
proceeded smoothly, forming aniline 66 in good yield (91%, reaction c).22,25 Reaction of aniline 
66 with acid chloride 20 using standard peptide coupling conditions led to the formation of S3I-
H224 in moderate yield, 53% (reaction d).22 A potential side product in reaction (d) may be from 
aniline 66 reacting with the pentafluorobenzene moiety of 20 through a SNAr reaction. 
 
 
Scheme 9: Synthesis of S3I-H224a 
 
aReagents and Conditions: (a) TFAA (1.3 eq), pyridine (2.2 eq), DCM, 0 to 25 °C, 1.5 h, 88%; (b) 3 (2.0 eq), NaI 
(0.2 eq), K2CO3 (2.0 eq), ACN, 65 °C, 24 h, 57%; (c) K2CO3 (2.0 eq), 1:1 THF/MeOH, 25 °C, 23 h, 91%; (d) 20 






2.7 Synthesis of S3I-H230 
 
 Synthetic route C (Scheme 2) was followed to synthesize S3I-H230 (Scheme 10). 
Aniline 66, previously synthesized as discussed in section 2.6, was reacted with acid chloride 35 
under peptide coupling reaction conditions producing 67 (reaction a).22 Side-products from 
reaction (a) could not be fully separated from anilide 67. Deprotection of impure anilide 67 in the 
presence of acid produced amine 68 in 42% over two steps from 66 (reaction b).22,28 Reaction of 
amine 68 with sulfonyl chloride 17 using DIPEA as a base produced the final product S3I-H230 
in 59% yield (reaction c).22 A potential side product contributing to the low yield in reaction (c) 
could again be from amine 68 reacting with the difluorocyanobenzene functionality of 17 
through a SNAr reaction.  
 
 
Scheme 10: Synthesis of S3I-H230a 
 
aReagents and Conditions: (a) 35 (2.1 eq), MeMgBr (2.5 eq), THF, 0 to 25 °C, 1.2 h; (b) TFA (37 eq), DCM, 25 °C, 










2.8 Synthesis of S3I-H235 
 
For the synthesis of S3I-H235 (Scheme 11) synthetic routes A (Scheme 1) and C 
(Scheme 2) were followed. Trifluoroacetamide 64 was exposed to 4 under SN2 reaction 
conditions forming 69 in good yield, 85% (reaction a).22 Deprotection of 69 using K2CO3 
produced 70 in 88% yield (reaction b).22,25 Anilide 71 was formed from the reaction of aniline 70 
with acid chloride 35 using MeMgBr as a base (reaction c).22 Side-products from reaction (c) 
could not be fully separated from anilide 71 by column chromatography and acid/base washes. 
Impure anilide 71 was deprotected under acidic conditions giving amine 72 in 41% yield over 
two steps from 70 (reaction d).22,28 The final compound, S3I-H235, was produced in 78% yield 




Scheme 11: Synthesis of S3I-H235a 
 
aReagents and Conditions: (a) 4 (1.3 eq), K2CO3 (4.0 eq), NaI (0.38 eq), ACN, 60 °C, 18 h, 85%; (b) K2CO3 (2.0 
eq), 1:1 THF/MeOH, 25 °C, 24 h, 88%; (c) 35 (2.1 eq), MeMgBr (2.5 eq), THF, 0 to 25 °C, 1.2 h; (d) TFA (37 eq), 








2.9 Synthesis of S3I-H233 
 
Target S3I-H233 (Scheme 12) was synthesized by following routes B (Scheme 1) and D 
(Scheme 2). N-Methylation of commercially available phthalazinone 73 proceeded smoothly and 
produced 74 in 84% yield (reaction a).33 The procedure reported in the literature for reaction (a) 
was followed although reaction times were slightly modified and the base was changed from 
NaH to KHMDS. Reaction of 74 with t-butyl carbamate using Buchwald-Hartwig amidation 
conditions produced carbamate 75 in good yield, 86% (reaction b).22 Carbamate 76 was formed 
in 85% yield by reacting 75 with 4 under standard SN2 reaction conditions (reaction c).22 
Deprotection of carbamate 76 using acid produced aniline 77 in 86% yield (reaction d).22,27 
Reacting aniline 77 with acid chloride 20 using peptide coupling reaction conditions gave the 
final product S3I-H233 in 38% yield (reaction e).22 Some side-products were formed in reaction 
(e) and aniline 77 was not fully consumed which contributed to the low yield. The phthalazinone 
functionality in aniline 77 may be withdrawing too much electron density from the nucleophilic 











Scheme 12: Synthesis of S3I-H233a 
 
aReagents and Conditions: (a) MeI (1.3 eq), KHMDS (1.2 eq), DMF, 0 to 25 °C, 23.2 h, 84%; (b) t-butyl carbamate 
(1.5 eq), Pd(OAc)2 (0.05 eq), Xantphos (0.05 eq), Cs2CO3, dioxane, 100 °C, 23 h, 86%; (c) 4 (1.3 eq), KHMDS (1.3 
eq), DMF, 0 to 25 °C, 15.5 h, 85%; (d) TFA (58 eq), DCM, 25 °C, 3 h, 86%; (e) 20 (1.5 eq), MeMgBr (1.3 eq), 
THF, 0 to 25 °C, 2.7 h, 38% 
 
2.91 Synthesis of S3I-H228 
 
The synthetic route for forming S3I-H228 is displayed below in Scheme 13. 
Commercially available 1-bromo-3-(difluoromethyl)benzene 78 was transformed into its 
carbamate derivative 79 in 63% yield using Buchwald-Hartwig coupling conditions (reaction 
a).22 Exposure of carbamate 79 to alkyl chloride 3 under SN2 reaction conditions produced 80 in 
86% yield (reaction b).22 Deprotection of carbamate 80 using TFA gave aniline 81 in 91% yield 
(reaction c).22,27 It was initially hypothesized that coupling aniline 81 with acid chloride 20 using 
a strong base like MeMgBr would lead to the formation of multiple products, because the pKa of 






To prevent the formation of multiple products in the final reaction, DMAP, an acyl transfer 
reagent, was utilized. Activation of acid chloride 20 with DMAP and subsequent reaction with 




Scheme 13: Synthesis of S3I-H228a 
 
aReagents and Conditions: (a) t-butyl carbamate (1.2 eq), Pd(OAc)2 (0.05 eq), Xantphos (0.05 eq), Cs2CO3 (2.0 eq), 
dioxane, 100 °C, 18 h, 63%; (b) 3 (1.3 eq), KHMDS (1.3 eq), DMF, 0 to 25 °C, 24.2 h, 86%; (c) TFA (58 eq), 
DCM, 25 °C, 3 h, 91%; (d) 20 (1.1 eq), DMAP (1.1 eq), DCM, 0 to 25 °C, 24.2 h, 79% 
 
 
2.92 Synthesis of S3I-H237 
 
For the synthesis of S3I-H237 (Scheme 14) synthetic route C (Scheme 2) was utilized. 
Aniline 81, previously synthesized as discussed in section 2.91, was exposed to acid chloride 35 
in the presence of MeMgBr producing anilide 82 in 63% yield (reaction a).22 Subsequent 







Unfortunately, reaction (b) led to the formation of many unidentified side products which could 
not be separated by column chromatography from amine 83. Impure amine 83 was exposed to 
sulfonyl chloride 17 in the presence of DIPEA giving sulfonamide S3I-H237 in 38% yield over 
two steps from 82 (reaction c).22 
 
 
Scheme 14: Synthesis of S3I-H237a 
 
aReagents and Conditions: (a) 35 (2.1 eq), MeMgBr (2.5 eq), THF, 0 to 25 °C, 1.2 h, 63%; (b) TFA (37 eq), DCM, 
25 °C, 1.5 h; (c) 17 (2.0 eq), DIPEA (5.0 eq), DCM, 0 to 25 °C, 1.7 h, 38% yield over two steps from 82 
 
 
2.93 Synthesis of S3I-H239 
 
Synthetic route B (Scheme 1) and a modified version of synthetic route D (Scheme 2) 
were used to prepare S3I-H239 (Scheme 15). The synthesis of S3I-H239 commenced by 
coupling carbamate 84 to alkyl chloride 3 using standard SN2 reaction conditions to produce 85 






acid led to the formation of aniline 86 in 72% yield (reaction b).22,27 It was initially thought that 
coupling aniline 86 with acid chloride 20 in the presence of a small strong nucleophilic base like 
MeMgBr might lead to the formation of unfavorable SNAr side-products. To prevent the 
formation of any SNAr side-products aniline 86 was coupled with acid chloride 20 in the 
presence of DMAP as a catalyst. This gave the final product S3I-H239 in 46% yield (reaction 
c).22 Aniline 86 was not fully consumed in reaction (c) which contributed to the low yield.  
 
 
Scheme 15: Synthesis of S3I-H239a 
 
aReagents and Conditions: (a) 3 (1.3 eq), KHMDS (1.3 eq), DMF, 0 to 25 °C, 20.2 h, 64%; (b) TFA (58 eq), DCM, 
25 °C, 3 h, 72%; (c) 20 (1.1 eq), DMAP (1.1 eq), DCM, 0 to 25 °C, 24 h, 46% 
 
 
2.94 Synthesis of S3I-H244 
 
To prepare target S3I-H244 (Scheme 16) synthetic route C (Scheme 2) was followed. 
Anilide 87 was formed in 60% yield using standard peptide coupling conditions (reaction a).22 
The anionic form of 86 is much more reactive with acid chloride 35 compared to its neutral form 






resulted in a mixture of products that could not be fully separated from amine 88 by column 
chromatography (reaction b).22,28 Impure amine 88 was reacted with sulfonyl chloride 17 in the 
presence of Hünig’s base producing the final compound S3I-H244 in 57% yield over two steps 
from 87 (reaction c).22 
 
 
Scheme 16: Synthesis of S3I-H244a 
 
aReagents and Conditions: (a) 35 (2.1 eq), MeMgBr (2.5 eq), THF, 0 to 25 °C, 1.2 h, 60%; (b) TFA (37 eq), DCM, 
25 °C, 1.5 h; (c) 17 (2.0 eq), DIPEA (5.0 eq), DCM, 0 to 25 °C, 1.7 h, 57% yield over two steps from 87 
 
 
2.95 Synthesis of S3I-H245 
 
Target S3I-H245 (Scheme 17) was synthesized by following routes B (Scheme 1) and C 
(Scheme 2). Carbamate 84 was coupled with 4 under SN2 reaction conditions producing 89 in 
83% yield (reaction a).22 Deprotection of intermediate 89 with TFA resulted in the formation of 
aniline 90 in 83% yield (reaction b).22,27 Reaction of intermediate 90 with acid chloride 35 in the 
presence of MeMgBr produced anilide 91 in 45% yield (reaction c).22 The lower than usual yield 






presence of adventitious water. Removal of the Boc protecting group from intermediate 91 
produced intermediate 92 (reaction d).22,28 Reaction (d) produced many side-products which 
could not be separated from amine 92 by column chromatography. Impure amine 92 was reacted 
with sulfonyl chloride 17 in the presence of DIPEA which led to the formation of the final 




Scheme 17: Synthesis of S3I-H245a 
 
aReagents and Conditions: (a) 4 (1.3 eq), KHMDS (1.3 eq), DMF, 0 to 25 °C, 19.2 h, 83%; (b) TFA (58 eq), DCM, 
25 °C, 3 h, 93%; (c) 35 (2.1 eq), MeMgBr (2.5 eq), THF, 0 to 25 °C, 1.2 h, 45%; (d) TFA (37 eq), DCM, 25 °C, 1.5 








 This concludes the synthesis of the STAT3 inhibitors S3I-H204, S3I-H212, S3I-H222, 
S3I-H224, S3I-H230, S3I-H235, S3I-H233, S3I-H228, S3I-H237, S3I-H239, S3I-H244, and 
S3I-H245 (Chapter 1, Figure 11). Each compound was characterized by 1H NMR and HRMS, 
purified to ≥ 95% purity as determined by LCMS, and sent to the UH Cancer Center to test for 
STAT3 DNA-binding inhibitory activity using the EMSA assay. The biological results will be 
discussed in Chapter 3. 
 Each of the STAT3 inhibitors (Figure 11) were designed and synthesized using 
convergent synthetic routes previously developed by our group (Chapter 2, Schemes 1 & 2).22 
These convergent synthetic routes have broad functional group tolerance which enables the 
development of a large library of molecules for screening. Most reactions with yields < 70% 
were not optimized, instead reaction intermediates and final compounds were carefully isolated 
and subjected to the next reaction step. In this medicinal chemistry project the goal was to isolate 
the desired molecules as fast as possible so relatively less time was spent on optimizing reaction 
conditions.  
 One important synthetic route that was modified was for the formation of alkyl chloride 3 
(Chapter 2, Scheme 3). Alkyl chloride 3 is an important building block found in most of our 
STAT3 inhibitors. It is necessary to have a high yielding synthetic route so that gram quantities 
of alkyl chloride 3 can easily be obtained. Synthetic route A was modified by changing the 
substrate in the initial Suzuki reaction (Route A, reaction a). The substrate was changed from 
pyridyl alcohol 23 to pyridyl ester 26. This prevented Pd0 chelation by the substrate and 
increased the reaction yield by 37% (Route B, reaction d). An additional reaction step was 






A procedure from the literature was followed for reaction (f) which utilized the mild reducing 
agent NaBH4 and catalytic NaOMe.30 These synthetic modifications (Route B) increased the 
overall yield of alkyl chloride 3 by 21% compared to Route A.  
 In some circumstances, it can be more efficient to try a new reaction sequence rather than 
optimize a low yielding reaction when in pursuit of a target molecule. This was demonstrated in 
the attempted synthesis of compound 41 (Schemes 6 & 7). Derivatization of S3I-H204 was 
initially attempted to form the N,N-dimethylsalicylamide derivative 41, but this reaction 
produced many side-products and 41 could not be isolated (Scheme 6). To optimize this 
reaction, S3I-H204 had to be resynthesized. Instead, an alternative synthetic route (Scheme 7) 
was utilized in the attempt to form 41. Although 41 could not be isolated using this synthetic 
route, its pyrazine analog S3I-H222 could be (Scheme 8).  
 Additionally, side-products 40, 42, and 53 isolated in the final reactions for forming S3I-
H212 and 41 demonstrate the reactivity of the difluorocyanobenzenesulfonamide functionality 
(Figures 13, 14, and 15). Side-products 40, 42, and 53 were formed by a SNAr reaction on the 
difluorocyanobenzenesulfonamide function of S3I-H212 and 41. These side-products lend 
credence to the importance of the difluorocyanobenzenesulfonamide unit in terms of biological 
activity. Reaction of the difluorocyanobenzenesulfonamide functionality in our STAT3 inhibitors 
with cysteine residues in the DNA binding domain of STAT3 represents an important 















































 To summarize, in Chapter 1 the importance of inhibiting STAT3 dimerization and the 
interaction of STAT3 with the DNA-binding domain to prevent the progression of cancerous 
transformations was discussed. Small molecule STAT3 inhibitors designed by our group were 
shown to disrupt STAT3 dimerization/DNA-binding and inhibited the growth of human breast 
and glioma tumor xenografts in mice. These results indicate that our small molecule STAT3 
inhibitors show promise as anti-cancer drugs. However, if our STAT3 inhibitors are to be 
developed into anti-cancer drugs the potency and physicochemical properties of these molecules 
need to be improved.  
 Extensive SAR analysis was performed to improve the potency and physicochemical 
properties of these inhibitors and from this analysis a general scaffold for the STAT3 inhibitors 
was developed (Chapter 1, Figure 7). It was found that the most potent compounds incorporate a 
cyclohexane ring in R1 and an azetidine in the linker region. It should be noted that the metabolic 
stability of the azetidine compounds still needs to be tested. The interplay between potency and 
the identity of the heteroarene ring, whether it is pyridine or pyrazine for the R2 functionality, 
needs to be better understood through the testing of more analogs incorporating this change. 
Additionally, it was shown that more analogs comparing the pentafluorobenzenesulfonamide and 
difluorocyanobenzenesulfonamide in R3 need to be examined to confirm that the 
difluorocyanobenzenesulfonamide functionality leads to the most potent compounds in the 
EMSA assay. It was established that functional groups that contain a carboxyl or hydroxamic 
acid in R4 have good potency but poor cell membrane permeability. Therefore, functionalities in 
R4 need to be varied to improve permeability and potency. In an effort to optimize R2, R3, and R4 
in terms of potency and physicochemical properties the targets shown below in Figure 16 were 


















 In Chapter 2 the synthesis of the target STAT3 inhibitors (S3I-H204, S3I-H212, S3I-
H222, S3I-H224, S3I-H230, S3I-H235, S3I-H233, S3I-H228, S3I-H237, S3I-H239, S3I-H244, 
and S3I-H245) was discussed. Each of the targets shown in Figure 16 is based on the 
azetidinamide scaffold and has two amine functionalities condensed with three different 
functionalities (R1 + R2, R3, and R4; Figure 7). The targets were designed and synthesized using 
convergent synthetic routes previously developed by our group (Chapter 2, Schemes 1 & 2). 
These convergent routes allowed for facile derivatization making it easy to build a complex 
library of molecules for screening. Overall, these synthetic routes have broad functional group 
tolerance and a wide substrate scope. It should be noted that most reactions with low yields (< 
70%) were not optimized, instead intermediates or final compounds were carefully isolated and 
subjected to the next reaction if necessary. This is the nature of synthesis in medical chemistry; 
little time is spent optimizing reactions so that the final compound can be synthesized as quickly 
as possible. Each target was synthesized, characterized, purified to ³ 95 % purity as determined 
by LCMS, characterized spectroscopically, and sent to the UH Cancer Center to test for STAT3 
DNA-binding inhibitory activity using the EMSA assay. The results from the EMSA assay are 
described below. 
Earlier SAR experiments showed that when the heteroarene in R2 is changed from 
pyridine to pyrazine the potency remains the same or slightly diminishes (Chapter 1, Figures 7 
& 8). To determine which heteroarene, pyridine or pyrazine, produces the most potent 
compounds S3I-H204, S3I-H222, S3I-H233, S3I-H230, S3I-H235, S3I-H244, and S3I-H245 
were compared with their pyridine or pyrazine analogs (Table 6). Conflicting potency results 






to produce S3I-H233 and S3I-H235 led to a decrease in potency. However, when the pyridine 
functionality in S3I-H204 is replaced by pyrazine to form S3I-H203 potency is enhanced, 0.786 
± 0.125 µM vs. 0.283 ± 0.031 µM. Unfortunately, S3I-H222 could not be compared to its 
pyridine analog, 41. Compound 41 could not be isolated, and once the low potency of S3I-H222 
was determined the synthesis of 41 was no longer pursued. Potency results for S3I-H245 are 
currently pending, but once the results of the EMSA assay are received, the potency of S3I-H245 
will be compared to its pyridine analog, S3I-H244.  
Table 6. Targeted STAT3 Compounds - SAR Variation in Region 2 (R2) 
 
 







 Earlier SAR experiments done by our group on region 3 (Chapter 1, Figure 7) revealed 
that when the pentafluorobenzenesulfonamide in S3I-H142 is replaced with 
difluorocyanobenzenesulfonamide to form S3I-H203 a slight increase in in vitro STAT3 DNA-
binding inhibition was observed, for example S3I-H142 IC50 = 0.42 µM vs. S3I-H203 IC50 = 
0.283 ± 0.031 µM (Chapter 1, Figure 10). To confirm that the 
difluorocyanobenzenesulfonamide is a better functionality to have in R3, compounds S3I-H212, 
S3I-H224, S3I-H230, S3I-H228, S3I-H237, S3I-H239, and S3I-H244 were compared to their 
difluorocyanobenzenesulfonamide or pentafluorobenzenesulfonamide analogs in terms of 
potency (Table 7). When the pentafluorobenzenesulfonamide group in S3I-H239 is replaced by 
difluorocyanobenzenesulfonamide to form S3I-H244 a substantial increase in potency is 
observed, S3I-H239 IC50 = > 4.0 µM vs. S3I-H244 IC50 = 0.978 ± 0.203 µM. Likewise, 
replacing the pentafluorobenzenesulfonamide functionality in S3I-H171 and S3I-H224 with 
difluorocyanobenzenesulfonamide led to the formation of S3I-H212 and S3I-H230, which 
slightly improved the STAT3 inhibitory potency (S3I-H212 IC50 = 0.711 ± 0.074 µM & S3I-
H230 IC50 = 0.632 ± 0.052 µM) compared to the parent compounds (S3I-H171 IC50 = 0.773 µM 
& S3I-H224 IC50 = 1.08 ± 0.05 µM). Interestingly, S3I-H212 and S3I-H230 had less potent half 
maximal effective concentrations (EC50) values in the breast cancer cell viability assay compared 
to their pentafluorobenzenesulfonamide derivatives S3I-H171 and S3I-H224, (S3I-H212 MDA-
231 EC50 = 2.7 µM & S3I-H230 MDA-231 EC50 = 4.4 µM vs. S3I-H171 MDA-231 EC50 = 1.7 
µM & S3I-H224 MDA-231 EC50 = 2.2 µM). This could be a result of the increased polarity of 
the difluorocyanobenzenesulfonamide group, which may make it more difficult for compounds 






Contrary to the comparisons discussed above, compound S3I-H237 containing the 
difluorocyanobenzenesulfonamide group suppressed STAT3 DNA-binding activity with lower 
activity compared to its pentafluorobenzenesulfonamide analog, S3I-H228 (S3I-H237 IC50 = 
2.58 ± 0.07 µM vs. S3I-H228 IC50 = 1.78 ± 0.28 µM). These results do not fit with expected 
trends and in the near future S3I-H228 and S3I-H237 will be re-tested and the potency of these 
two compounds will be compared. Altogether the EMSA IC50 results from S3I-H212, S3I-H230, 
S3I-H224, S3I-H244, and S3I-H239 confirm that when R3 = difluorocyanobenzenesulfonamide 
compounds have better potency compared to compounds that have R3 = 
pentafluorobenzenesulfonamide.  
 
Table 7. Targeted STAT3 Compounds - SAR Variation of Region 3 (R3) 
 
 
Note: R3 in each compound is highlighted in red, and all IC50 values were obtained using the EMSA assay 
 
 In Chapter 1 it was shown that STAT3 inhibitors that contain a carboxyl or hydroxamic 






Compounds with a carboxyl or hydroxamic acid group in R4 have poor cellular permeability, 
because these polar functional groups make it difficult for these molecules to traverse the non-
polar cell membrane. In hopes of simultaneously increasing permeability and potency, various 
functionalities in the aromatic ring of R4 were examined (Figure 11, Table 8). When the 
salicylic acid functionality in S3I-H204 was converted to its less polar N-methylsalicylamide 
analog S3I-H212 a slight increase in STAT3 DNA-binding inhibition was observed, S3I-H204 
IC50 = 0.786 ± 0.125 µM vs. S3I-H212 IC50 = 0.711 ± 0.074 µM. However, N,N-
dimethylsalicylamide S3I-H222 performed worse in the EMSA assay compared to its salicylic 
analog S3I-H203 (S3I-H222 IC50 = 2.25 ± 0.04 µM vs. S3I-H203 IC50 = 0.283 ± 0.031 µM). 
Similarly, meta-difluoromethylbenzene and meta-fluorobenzene (S3I-H237 and S3I-H244) 
showed weaker in vitro activity compared to the parent compound, S3I-H204 (S3I-H237 IC50 = 
2.58 ± 0.07 µM & S3I-H244 IC50 = 0.978 ± 0.203 µM vs. S3I-H204 IC50 = 0.786 ± 0.125 µM). 
These results suggest that the salicylic acid functionality in R4 can be replaced by the N-
methylsalicylamide group for STAT3 inhibitory activity to be maintained.  
Permeability test results on S3I-H212, S3I-H222, S3I-H237, and S3I-H244 were not obtained, 
because all of these compounds have similar or lower STAT3 inhibitory activity than the parent 
compounds, S3I-H203 and S3I-H204.  
 Interestingly, removing all the functional groups on the benzene ring in R4 enhanced in 
vitro activity. This was observed when comparing S3I-H230 with its salicylic acid analog S3I-
H204 (S3I-H230 IC50 = 0.632 ± 0.052 µM vs. S3I-H204 IC50 = 0.786 ± 0.125 µM). 
Additionally, S3I-H230 showed increased STAT3 DNA-binding inhibition compared to its 






0.132 µM). These results suggest that the salicylic acid functional group in R4 is superfluous. 
Additional SAR experiments are underway to verify this statement. Furthermore, the less polar 
benzene group in S3I-H230 should render this molecule more permeable than its salicylic acid 
analog, S3I-H204. Moreover, the low molecular weight of S3I-H230 should make it easier for 
this molecule to traverse cells compared to its higher molecular weight analogs. Cellular 
permeability tests on S3I-H230 will be obtained in the near future.  
 
Table 8. Targeted STAT3 Compounds - SAR Variation of Region 4 (R4) 
 
 
Note: R4 in each compound is highlighted in purple, and all IC50 values were obtained using the EMSA assay  
 
To summarize, 12 small molecule STAT3 inhibitors were designed, synthesized, 
characterized spectroscopically, and sent to the UH Cancer Center to test for STAT3 DNA-
binding inhibitory activity using the EMSA assay. The biological results for S3I-H204, S3I-
H222, S3I-H230, S3I-H235, S3I-H233, S3I-H244, and S3I-H245 indicate that more analogs 
comparing pyridine and pyrazine need to be explored to resolve which heterocycle in region 2 






H212, S3I-H224, S3I-H230, S3I-H239, and S3I-H244 confirmed that compounds with R3 = 
difluorocyanobenzenesulfonamide have better potency compared to their analogs with R3 = 
pentafluorobenzenesulfonamide (Figure 7, Table 7). Compounds with R4 =  
N-methylsalicylamide, N,N-dimethylsalicylamide, meta-difluoromethylbenzene, or meta-
fluorobenzene (S3I-H212, S3I-H222, S3I-H237, and S3I-H244) had similar or lower STAT3 
inhibitory activity than the parent compounds with R4 = salicylic acid (Figure 7, Table 8). 
Replacing the salicylic acid functionality with benzene led to enhanced in vitro activity (S3I-
H230 vs. S3I-H204). This suggests that functional groups on the benzene ring in R4 are not 

































































1H NMR, and 19F NMR were recorded on an Agilent DD2 spectrometer at 300 MHz (1H), 75 
MHz (13C), 282 MHz (19F) or on a Varian Unity Inova spectrometer at 500 MHz (1H) and 125 
MHz (13C). Chemical shifts (δ) are reported in parts per million (ppm) and are referenced to the 
solvent, i.e., 7.26/77.2 for CDCl3 and 2.50/39.5 for DMSO-d6. Multiplicities are listed as: s 
(singlet), d (doublet), dd (doublet of doublets), ddd (doublet of doublet of doublets), t (triplet), q 
(quartet), quint (quintet), or m (multiplet). Coupling constants (J) are reported in Hertz (Hz). 
Thin-Layer Chromatography (TLC) was performed on Silicycle TLC glass plates, 250 µM, pore 
size 60	Å. Flash column chromatography was performed on Natland silica gel, 230-400 mesh. 
Preparative thin-layer chromatography was performed on Analtech uniplate prep TLC plates, 
1000 µm. All moisture sensitive reactions were performed under at static atmosphere of argon in 
oven-dried or flame-dried glassware. Purity and homogeneity of all materials was determined to 
be at least 95% from TLC, 1H NMR, LCMS, and 19F NMR when applicable. Final compounds 
prepared for biological examination were purified to ³ 95% and evaluated at 254 nm by C18 
reverse phase HPLC using an Agilent 6410 triple quadrupole LCMS. High resolution mass 
spectrometric data were obtained on an Agilent LC-MS TOF with ESI ionization in positive 











Synthesis of 27. To a two-neck round-bottom flask equipped with a stir bar was added methyl 5-
bromopicolinate 26 (300 mg, 1.39 mmol, 1.0 eq), SPhos (57 mg, 0.139 mmol, 0.1 eq), 1-
cyclohexenylboronic acid (350 mg, 2.78 mmol, 2.0 eq), and potassium phosphate tribasic (590 
mg, 2.78 mmol, 2.0 eq). The flask was exchanged with Ar (g) (x 3) before dry THF (6 mL) and 
HPLC Grade H2O (0.05 mL, 2.78 mmol, 2.0 eq) were added. Then Pd(OAc)2 (16 mg, .0695 
mmol, 0.05 eq) was added to the mixture and the flask was exchanged with Ar (g) (x 3). The 
mixture was stirred for 24 hours at 40 °C. After reaction completion, water was added to the 
mixture. The crude reaction mixture was extracted with ethyl acetate, and the combined ethyl 
acetate extracts were washed with water and brine and dried over anhydrous sodium sulfate. 
Purification via column chromatography (3:1 hexanes/ethyl acetate) gave the product 27 as a 
white solid (248 mg, 82% yield). Spectral data: 1H NMR (300 MHz, Chloroform-d) δ 8.73 (d, J 
= 2.3 Hz, 1H), 8.05 (dd, J = 8.2, 0.8 Hz, 1H), 7.74 (dd, J = 8.2, 2.3 Hz, 1H), 6.42 – 6.15 (m, 1H), 
3.98 (s, 3H), 2.47 – 2.34 (m, 2H), 2.27 – 2.18 (m, 2H), 1.86 – 1.73 (m, 2H), 1.72 – 1.61 (m, 2H); 
HRMS (ESI) m/z = 240.1001 [M+Na]+, HRMS (ESI+) calculated for C13H15NO2: 217.1103, 











Synthesis of 28. To a round-bottom flask equipped with a stir bar was added alkene 27 (430 mg, 
1.98 mmol, 1.0 eq) followed by platinum oxide (43 mg, 0.189 mmol, 0.1 eq). The flask was 
exchanged with Ar (g) (x 3) before being exchanged with H2 (g) (x 3). Ethyl acetate (3.5 mL) and 
methanol (3.5 mL) were then added. After stirring for four hours at room temperature, the 
mixture was filtered through a CeliteÒ plug and solvent was evaporated under reduced pressure. 
This afforded product 28 as a white solid (417 mg, 96% yield). Spectral data: 1H NMR (500 
MHz, Chloroform-d) δ 8.59 (d, J = 2.2 Hz, 1H), 8.06 (d, J = 8.1 Hz, 1H), 7.66 (dd, J = 8.1, 2.2 
Hz, 1H), 3.99 (s, 3H), 2.68 – 2.55 (m, 1H), 1.93 – 1.82 (m, 5H), 1.49 – 1.35 (m, 5H); HRMS 


















Synthesis of 25. To a round-bottom flask equipped with a stir bar was added a solution of ester 
28 (636 mg, 2.90 mmol, 1.0 eq) in methanol (16 mL) followed by sodium methoxide (158 mg, 
2.93 mmol, 1.01 eq). The reaction mixture was heated to 50 °C and powdered sodium 
borohydride was added (658 mg, 17.4 mmol, 6 eq). After one hour additional sodium methoxide 
(22 mg, .406 mmol, 0.14 eq) and sodium borohydride (110 mg, 2.90 mmol, 1.0 eq) were added 
to the mixture. After stirring for 2 hours at 50 °C the reaction was complete. After cooling to 
room temperature, the reaction mixture was quenched with saturated ammonium chloride (5 mL) 
and extracted with ethyl acetate. The combined organic extracts were washed with water and 
brine and dried with anhydrous sodium sulfate. Purification via column chromatography (1:1 
hexanes/ethyl acetate) gave the product 25 as a clear oil (444 mg, 80% yield). Spectral data: 1H 
NMR (300 MHz, Chloroform-d) δ 8.38 (d, J = 2.2 Hz, 1H), 7.50 (dd, J = 8.0, 2.2 Hz, 1H), 7.18 
(d, J = 8.0 Hz, 1H), 4.71 (s, 2H), 2.62 – 2.41 (m, 1H), 1.97 – 1.68 (m, 5H), 1.51 – 1.13 (m, 5H); 
HRMS (ESI) m/z = 214.1170 [M+Na]+, HRMS (ESI+) calculated for C12H17NO: 191.1310, 














Synthesis of 3. To an oven-dried round-bottom flask equipped with a stir bar was added alcohol 
25 (1 g, 5.23 mmol, 1.0 eq) followed by DCM (20.0 mL) under an atmosphere of argon. The 
solution was cooled and stirred for two minutes at 0 °C before SOCl2 (0.58 mL, 7.80 mmol, 1.53 
eq) was added. The solution was warmed to room temperature, stirred for 3 hours, and quenched 
with sat. NaHCO3. DCM was used to extract the product which was washed with sat. NaHCO3, 
dried over Na2SO4, and solvent was condensed in vacuo. This process gave the product 3 (1.10 g, 
100% yield) as a yellow oil which was immediately diluted to 0.5M with dry toluene and stored 





















Synthesis of 30. To a round-bottom flask equipped with a stir bar was added 29 (2.0 g, 5.50 
mmol, 1.0 eq) followed by NH4Cl (3.0 g, 56.1 mmol, 10.2 eq), ethanol (20 mL), and HPLC-
grade water (10 mL) under an argon atmosphere. Iron powder (1 g, 38.5 mmol, 7.0 eq) was 
added and the mixture was stirred rigorously overnight at 66 °C. After stirring for 16 hours the 
reaction was complete. The mixture was filtered through a CeliteÒ plug and rinsed with ethyl 
acetate. The filtrate was washed with water and brine and dried with Na2SO4. The solvent was 
removed in vacuo to afford compound 30 as a white solid (1.66 g, 91% yield). Spectral data: 1H 
NMR (300 MHz, Chloroform-d) δ 7.81 (d, J = 9.0 Hz, 1H), 7.54 – 7.27 (m, 10H), 6.28 – 6.22 
(m, 2H), 5.30 (s, 2H), 5.12 (s, 2H), 4.01 (s, 2H); HRMS (ESI) m/z = 356.1266 [M+Na]+, HRMS 


















Synthesis of 31. To a solution of amine 30 (500 mg, 1.49 mmol, 1.0 eq) in DCM (8.0 mL) was 
added pyridine (0.26 mL, 3.26 mmol, 2.19 eq), followed by TFAA (0.23 mL, 1.64 mmol, 1.10 
eq) under an argon atmosphere at 0 °C. The reaction mixture was warmed to 25 °C. After stirring 
for 3.5 hours, the reaction mixture was diluted with DCM and washed with sat. Na2SO4 and sat. 
NaHCO3. The organic layer was dried with anhydrous Na2SO4 and the solvent was condensed in 
vacuo. Purification by flash chromatography (7:3 hexanes/ethyl acetate) yielded the product 31 
(538 mg, 84% yield) as a white-orange solid. Spectral data: 1H NMR (300 MHz, Chloroform-d) 
δ 8.00 (s, 1H), 7.92 (d, J = 8.4 Hz, 1H), 7.64 (d, J = 2.0 Hz, 1H), 7.49 – 7.29 (m, 10H), 6.97 (dd, 
J = 8.4, 2.0 Hz, 1H), 5.34 (s, 2H), 5.19 (s, 2H); HRMS (ESI) m/z = 452.1063 [M+Na]+, HRMS 


















Synthesis of 32. To a round-bottom flask equipped with a stir bar was added NaI (21 mg, 0.140 
mmol, 0.2 eq), K2CO3 (193 mg, 1.40 mmol, 2.0 eq), and trifluoroacetamide 31 (300 mg, 0.699 
mmol, 1.0 eq) under an argon atmosphere. Dry acetonitrile (9 mL) was then added, followed by 
alkyl chloride 3 (2.0 mL, 0.978 mmol, 1.4 eq). The reaction mixture was warmed to 65 °C and 
stirred for 24 hours. After cooling to room temperature, the reaction mixture was quenched with 
water. The aqueous phase was extracted with ethyl acetate and the combined organic extracts 
were washed with brine and dried with anhydrous Na2SO4. The solvent was condensed in vacuo 
to yield the crude product. Purification by flash chromatography (10:1 to 8:2 hexanes/ethyl 
acetate) yielded the product 32 as a light-yellow oil (268 mg, 64% yield). Spectral data: 1H NMR 
(300 MHz, Chloroform-d) δ 8.38 (d, J = 2.3 Hz, 1H), 7.83 (d, J = 8.2 Hz, 1H), 7.48 (dd, J = 8.0, 
2.3 Hz, 1H), 7.42 – 7.28 (m, 10H), 7.17 (d, J = 8.0 Hz, 1H), 6.93 (d, J = 1.8 Hz, 1H), 6.87 (dd, J 
= 8.2, 1.8 Hz, 1H), 5.33 (s, 2H), 5.02 (s, 2H), 4.97 (s, 2H), 2.59 – 2.44 (m, 1H), 1.95 – 1.67 (m, 
5H), 1.49 – 1.18 (m, 5H); HRMS (ESI) m/z = 625.2297 [M+Na]+, HRMS (ESI+) calculated for 












Synthesis of 33. To a solution of trifluoroacetamide 32 (136 mg, 0.225 mmol, 1.0 eq) in 1:1 
THF/MeOH (1.0 mL) was added K2CO3 (62 mg, 0.450 mmol, 2.0 eq) under an argon 
atmosphere. After stirring for 20 hours at 25 °C the reaction was complete and was quenched 
with sat. NH4Cl. The reaction mixture was extracted with ethyl acetate, washed with brine, dried 
over anhydrous Na2SO4, and solvent was removed in vacuo. This process yielded the product 33 
as a white solid (112 mg, 98% yield). Spectral data: 1H NMR (300 MHz, Chloroform-d) δ 8.42 
(d, J = 2.2 Hz, 1H), 7.85 (d, J = 8.5 Hz, 1H), 7.52 – 7.27 (m, 11H), 7.18 (d, J = 8.0 Hz, 1H), 6.41 
– 6.14 (m, 2H), 5.38 – 5.18 (m, 3H), 5.11 (s, 2H), 4.42 (d, J = 5.1 Hz, 2H), 2.64 – 2.43 (m, 1H), 
1.99 – 1.69 (m, 5H), 1.52 – 1.21 (m, 5H); HRMS (ESI) m/z = 529.2469 [M+Na]+, HRMS (ESI+) 

















Synthesis of 35. To a round-bottom flask equipped with a stir bar was added carboxylic acid 34 
(122 mg, 0.607 mmol, 1.0 eq) followed by DCM (3.0 mL) under an argon atmosphere. A bubbler 
was attached to the reaction flask and (COCl)2 (60 uL, 0.709 mmol, 1.17 eq) and DMF (2 drops) 
were added. After stirring for 1.5 hours at 25 °C the reaction was complete. The stir bar was 
removed and the solvent was condensed in vacuo, the remaining oil was dried on the high 
vacuum for 1 hour. This process yielded the product 35 as a yellow oil (133 mg, 100% yield) 





















Synthesis of 36. Note: Water was removed azeotropically from amine 33 with anhydrous toluene 
prior to use. To an oven-dried round-bottom flask equipped with a stir bar was added amine 33 
(147 mg, 0.289 mmol, 1.0 eq) followed by dry THF (3.0 mL) under an argon atmosphere. The 
solution was stirred at 0 °C for 2 minutes before MeMgBr (0.52 mL, 0.723 mmol, 2.5 eq) was 
added. The solution was allowed to stir at 0 °C for 10 minutes before acid chloride 35 (133 mg, 
0.607 mmol, 2.1 eq) in THF (3.0 mL) was added. The solution was warmed to 25 °C, stirred for 
1 hour, and quenched with water. The reaction mixture was extracted with ethyl acetate, washed 
with brine, dried over anhydrous Na2SO4, and solvent was removed in vacuo. Purification by 
flash chromatography using 1:1 hexanes/ethyl acetate gave the product 36 as a clear oil (150 mg, 
75% yield). Spectral data: 1H NMR (300 MHz, Chloroform-d) δ 8.31 (d, J = 2.0 Hz, 1H), 7.80 
(d, J = 8.3 Hz, 1H), 7.46 (dd, J = 8.0, 2.0 Hz, 1H), 7.41 – 7.28 (m, 10H), 7.21 – 7.06 (m, 1H), 
6.97 – 6.68 (m, 2H), 5.33 (s, 2H), 5.18 – 4.86 (m, 4H), 4.70 – 4.43 (m, 1H), 4.11 – 3.94 (m, 1H), 
3.81 – 3.62 (m, 1H), 2.56 – 2.42 (m, 1H), 2.13 – 1.90 (m, 2H), 1.90 – 1.75 (m, 5H), 1.57 – 1.19 
(m, 14H); HRMS (ESI) m/z = 712.3364 [M+Na]+, HRMS (ESI+) calculated for C42H47N3O6: 










Synthesis of 38. To a solution of carbamate 36 (141 mg, 0.204 mmol, 1.0 eq) in DCM (2.0 mL) 
was added TFA (0.58 mL, 7.55 mmol, 37.0 eq) at 25 °C under an argon atmosphere. After 
stirring for 1.5 hours the reaction was complete. Solvent was removed on the rotary evaporator 
and then water and ethyl acetate were added to the residue. The ethyl acetate layer was washed 
with brine, dried over anhydrous Na2SO4, and solvent was removed in vacuo. Purification via 
flash chromatography yielded amine 37 (105 mg) which was used in the following reaction. To a 
round-bottom flask equipped with a stir bar was added 37 (105 mg, 0.178 mmol, 1.0 eq) 
followed by DCM (1.9 mL) under an atmosphere of argon. The solution was allowed to stir at 0 
°C for 2 minutes before DIPEA (0.16 mL, 0.891 mmol, 5.0 eq) was added. The solution was 
stirred at 0 °C for 10 minutes before sulfonyl chloride 17 (85 mg, 0.356 mmol, 2.0 eq) in DCM 
(1.8 mL) was added. After stirring for 2 hours at 25 °C the reaction was complete. The reaction 
was quenched with water, extracted with DCM, washed with brine, and dried over anhydrous 
Na2SO4. Solvent was condensed on the rotary evaporator and purification by flash 








1H NMR (300 MHz, Chloroform-d) δ 8.36 (d, J = 2.3 Hz, 1H), 8.21 – 8.11 (m, 1H), 8.09 – 8.03 
(m, 1H), 7.82 (d, J = 8.2 Hz, 1H), 7.48 (dd, J = 8.0, 2.3 Hz, 1H), 7.43 – 7.28 (m, 10H), 7.19 (d, J 
= 8.0 Hz, 1H), 6.88 (d, J = 1.9 Hz, 1H), 6.80 (dd, J = 8.2, 1.9 Hz, 1H), 5.42 – 4.74 (m, 7H), 3.99 
– 3.83 (m, 1H), 3.63 – 3.44 (m, 1H), 2.57 – 2.44 (m, 1H), 2.15 – 1.99 (m, 1H), 1.95 – 1.66 (m, 
6H), 1.50 – 1.14 (m, 5H); HRMS (ESI) m/z = 813.2532 [M+Na]+, HRMS (ESI+) calculated for 





















Synthesis of S3I-H204. To a round-bottom flask equipped with a stir bar was added sulfonamide 
38 (97 mg, 0.122 mmol, 1.0 eq) followed by 15% by weight 1:1 Pd/C and Pd(OH)2 (.015 g each) 
and 1:1 ethyl acetate/methanol (2.2 mL). The mixture was exchanged with hydrogen gas three 
times before stirring at 25 °C. After 5 hours, an additional 10% by weight Pd/C and Pd(OH)2 
(.006 g each) was added and the flask was exchanged with hydrogen gas three times before being 
allowed to stir at 25 °C. After stirring for 18 hours at 25 °C the reaction was complete. The 
mixture was flushed through a CeliteÒ plug with ethyl acetate containing 10% methanol. The 
filtrate was concentrated and the crude material was purified via prep-TLC. This process gave 
the product S3I-H204 (37 mg, 50% yield) as a white solid. 1H NMR (300 MHz, DMSO-d6) δ 
8.34 (d, J = 2.2 Hz, 1H), 8.29 – 8.20 (m, 1H), 8.18 – 8.04 (m, 1H), 7.73 – 7.51 (m, 2H), 7.24 (d, 
J = 8.1 Hz, 1H), 6.60 – 6.39 (m, 2H), 4.99 – 4.49 (m, 3H), 3.87 – 3.56 (m, 2H), 2.36 – 2.18 (m, 
1H), 1.98 – 1.57 (m, 6H), 1.52 – 1.16 (m, 5H); HPLC purity: 100 %; HRMS (ESI) m/z = 
611.1768 [M+H]+, HRMS (ESI+) calculated for C30H28F2N4O6S: 610.1698, found 610.1695; 











Synthesis of S3I-H212. To a round-bottom flask equipped with a stir bar was added S3I-H204 
(51 mg, 0.0829 mmol, 1.0 eq) in DCM (2.3 mL). The mixture was allowed to stir at 0 °C for 2 
minutes before DIPEA (13 µL, 0.0746 mmol, 0.9 eq) and HATU (32 mg, 0.0829 mmol, 1.0 eq) 
were added. This solution was allowed to stir for 1.5 hours at 25 °C before being cooled to -10 
°C. After stirring for 2 minutes at -10 °C, methylamine (72 µL, 0.144 mmol, 1.74 eq) and 
DIPEA (14.4 µL, 0.0829 mmol, 1.0 eq) were added and the solution was allowed to stir at -10 
°C. After stirring for 3 hours and 45 minutes at -10 °C the reaction was complete. The reaction 
mixture was quenched with sat. NH4Cl, extracted with DCM, dried with anhydrous Na2SO4, and 
concentrated in vacuo. The crude product was purified via prep-TLC yielding the product S3I-
H212 (4 mg, 9.0% yield) as a white powder. 1H NMR (300 MHz, Chloroform-d) δ 12.64 (s, 1H), 
8.34 (s, 1H), 8.18 – 8.07 (m, 1H), 8.03 – 7.95 (m, 1H), 7.50 (dd, J = 8.1, 2.2 Hz, 1H), 7.41 (d, J 
= 8.9 Hz, 1H), 7.26 – 7.23 (m, 1H), 6.79 – 6.70 (m, 2H), 6.61 – 6.51 (m, 1H), 5.07 – 4.82 (m, 
3H), 4.02 – 3.85 (m, 1H), 3.78 – 3.60 (m, 1H), 3.01 (d, J = 4.8 Hz, 3H), 2.57 – 2.31 (m, 2H), 
2.09 – 1.90 (m, 1H), 1.90 – 1.55 (m, 5H), 1.51 – 1.15 (m, 5H); HPLC purity: 100 %; HRMS 
(ESI) m/z = 646.1933 [M+Na]+, HRMS (ESI+) calculated for C31H31F2N5O5S: 623.2014, found 








Synthesis of 44. To a suspension of 2-hydroxy-4-nitrobenzoic acid 43 (500 mg, 2.730 mmol, 1.0 
eq) in DCM (25.0 mL) was added DIPEA (0.43 mL, 2.451 mmol, 0.9 eq) at 25 °C under an 
argon atmosphere. This solution was stirred for 2 minutes 0 °C before HATU (1.04 g, 2.730 
mmol, 1.0 eq) was added. The solution was warmed to 25 °C and stirred for 1.5 hours before 
NHMe2 (2.0 mL, 4.0 mmol, 1.5 eq) was added. After 24.3 hours, the reaction was quenched with 
water, extracted with DCM, dried over anhydrous Na2SO4, and solvent was condensed in vacuo. 
Purification by flash chromatography (2:1 hexanes/ethyl acetate) yielded the product 44 (310 
mg, 54% yield) as a white solid. 1H NMR (300 MHz, Chloroform-d) δ 7.85 (d, J = 2.3 Hz, 1H), 
7.73 (dd, J = 8.6, 2.3 Hz, 1H), 7.49 (d, J = 8.6 Hz, 1H), 3.21 (s, 6H). HRMS (ESI) m/z = 




















Synthesis of 45. To a round-bottom flask equipped with a stir bar was added 2-hydroxy-N,N-
dimethyl-4-nitrobenzamide 44 (761 mg, 3.62 mmol, 1.0 eq) followed by K2CO3 (601 mg, 4.35 
mmol, 1.2 eq) under an atmosphere of argon. DMF (22.0 mL) was added and suspension was 
stirred for 10 minutes at 25 °C before BnBr (0.47 mL, 3.98 mmol, 1.1 eq) was added. The 
reaction was stirred for 32 hours, quenched with water, extracted with ethyl acetate, washed with 
brine, dried over anhydrous Na2SO4, and solvent was condensed in vacuo. Purification by flash 
chromatography (1:1 hexanes/ethyl acetate) gave the product 45 (918 mg, 84% yield) as a white 
solid. 1H NMR (300 MHz, Chloroform-d) δ 7.92 – 7.86 (m, 1H), 7.83 (d, J = 2.0 Hz, 1H), 7.47 – 
7.30 (m, 6H), 5.21 (s, 2H), 3.11 (s, 3H), 2.83 (s, 3H); HRMS (ESI) m/z = 323.1000 [M+Na]+, 















Synthesis of 46. To a solution of 2-(benzyloxy)-N,N-dimethyl-4-nitrobenzamide 45 (181 mg, 
0.601 mmol, 1.0 eq) and NH4Cl (328 mg, 6.12 mmol, 10.2 eq) in ethanol (2.2 mL) and HPLC-
grade water (1.1 mL) was added iron powder (109 mg, 4.21 mmol, 7.0 eq) under an argon 
atmosphere. The suspension was allowed to stir vigorously for 20 hours at 66 °C. The suspension 
was cooled to room temperature and filtered through a CeliteÒ plug which was rinsed with ethyl 
acetate. The ethyl acetate layer was washed with water and brine, dried over anhydrous Na2SO4, 
and the solvent was condensed in vacuo. This process yielded the product 46 (141 mg, 87% 
yield) as a light orange solid. 1H NMR (300 MHz, Chloroform-d) δ 7.39 – 7.27 (m, 5H), 7.09 (d, 
J = 8.1 Hz, 1H), 6.30 (dd, J = 8.1, 2.0 Hz, 1H), 6.24 (d, J = 2.0 Hz, 1H), 5.05 (s, 2H), 3.78 (s, 
2H), 3.07 (s, 3H), 2.87 (s, 3H); HRMS (ESI) m/z = 293.1260 [M+Na]+, HRMS (ESI+) calculated 
















Synthesis of 47. To a solution of amine 46 (120 mg, 0.444 mmol, 1.0 eq) in DCM (2.5 mL) was 
added pyridine (87 µL, 1.08 mmol, 2.2 eq) under an atmosphere of argon. The solution was 
stirred at 0 °C for 2 minutes before TFAA (68 µL, 0.489 mmol, 1.1 eq) was added and then 
warmed to room temperature. After stirring for 1.5 hours the reaction was complete. The solution 
was diluted with DCM, washed with Sat. Na2SO4, washed with Sat. NaHCO3, dried over 
anhydrous Na2SO4, and solvent was condensed in vacuo. Purification by flash chromatography 
(2:1 hexanes/ethyl acetate) gave the product 47 (115 mg, 71% yield) as a light orange white 
solid. 1H NMR (300 MHz, Chloroform-d) δ 10.31 (s, 1H), 7.35 – 7.15 (m, 6H), 7.02 – 6.90 (m, 
2H), 4.86 – 4.57 (m, 2H), 3.08 (s, 3H), 2.79 (s, 3H); HRMS (ESI) m/z = 389.1082 [M+Na]+, 
















Synthesis of 55. To a round-bottom flask equipped with a stir bar was added methyl 5-
bromopyrazine-2-carboxylate 54 (1.25 g, 5.76 mmol, 1.0 eq), cyclohex-1-en-1-ylboronic acid 
(1.09 g, 8.64 mmol, 1.5 eq), K3PO4 (2.45 g, 11.5 mmol, 2.0 eq), Pd(OAc)2 (65 mg, 0.288 mmol, 
0.05 eq), and SPhos (237 mg, 0.576 mmol, 0.1 eq) under an argon atmosphere. The solids were 
then exchanged with an argon atmosphere (x 3) before dry THF (19.2 mL) and HPLC-grade 
water (0.21 mL) were added. The solution was exchanged with argon (x 3) before being stirred 
for 22 hours at 40 °C. The reaction was quenched with water and extracted with ethyl acetate. 
The combined organic extracts were washed with brine, dried over anhydrous Na2SO4, and 
solvent was condensed in vacuo. Purification by flash chromatography (17:3 hexanes/ethyl 
acetate) gave the product 55 (1.04 g, 83% yield). 1H NMR (500 MHz, Chloroform-d) δ 9.17 (d, J 
= 1.5 Hz, 1H), 8.76 (d, J = 1.5 Hz, 1H), 6.98 – 6.92 (m, 1H), 4.01 (s, 3H), 2.57 – 2.49 (m, 2H), 
2.37 – 2.25 (m, 2H), 1.86 – 1.76 (m, 2H), 1.73 – 1.64 (m, 2H); HRMS (ESI) m/z = 241.0956 














Synthesis of 56. To a solution of alkene 55 (3.30 g, 15.2 mmol, 1.0 eq) in 1:1 ethyl 
acetate/methanol (52.0 mL) was added PtO2 (330 mg, 1.45 mmol, 10% by weight). The 
suspension was exchanged with hydrogen gas (x 3) before being stirred for 20.5 hours at 25 °C. 
The suspension was filtered through a CeliteÒ plug, the CeliteÒ plug was rinsed with ethyl 
acetate, and solvent was condensed in vacuo. Purification by flash chromatography (4:1 hexanes 
/ethyl acetate to 100% ethyl acetate) gave the product 56 (1.72 g, 52% yield). 1H NMR (300 
MHz, Chloroform-d) δ 9.17 (d, J = 1.5 Hz, 1H), 8.53 (d, J = 1.5 Hz, 1H), 3.99 (s, 3H), 2.91 – 
2.73 (m, 1H), 2.01 – 1.17 (m, 10H); HRMS (ESI) m/z = 243.1112 [M+Na]+, HRMS (ESI+) 


















Synthesis of 57. To a round-bottom flask equipped with a stir bar was added ester 56 (1.72 g, 
7.81 mmol, 1.0 eq) followed by methanol (40.0 mL) under an atmosphere of argon. The solution 
was stirred for 2 minutes at 0 °C before powdered NaBH4 (886 mg, 23.4 mmol, 3.0 eq) was 
added. The solution was warmed to room temperature, stirred for 25 minutes, and solvent was 
condensed in vacuo. The crude product was extracted with ethyl acetate, washed with brine, 
dried over anhydrous Na2SO4, and solvent was condensed in vacuo. Purification by flash 
chromatography (9:11 hexanes/ethyl acetate) gave the product 57 (1.26 g, 84% yield) as a yellow 
oil. 1H NMR (300 MHz, Chloroform-d) δ 8.52 (d, J = 1.5 Hz, 1H), 8.38 (d, J = 1.5 Hz, 1H), 4.78 
(s, 2H), 3.65 (s, 1H), 2.82 – 2.63 (m, 1H), 1.98 – 1.16 (m, 10H); HRMS (ESI) m/z = 385.2504 

















Synthesis of 4. To a solution of alcohol 57 (200 mg, 1.04 mmol, 1.0 eq) in DCM (5.2 mL) was 
added trimethylamine (0.43 mL, 3.12 mmol, 3.0 eq) under an argon atmosphere. The solution 
was stirred at 0 °C for 2 minutes before MsCl (0.15 mL, 1.93 mmol, 1.86 eq) was added. The 
remaining solution was stirred for 30 minutes at 0 °C before being quenched with Sat. NaHCO3. 
The crude product was extracted with ethyl acetate, washed with brine, dried over anhydrous 
Na2SO4, and solvent was condensed in vacuo. Purification by flash chromatography gave the 
product 4 (237 mg, 84% yield) as a pink solid. 1H NMR (300 MHz, Chloroform-d) δ 8.55 (d, J = 
1.5 Hz, 1H), 8.39 (d, J = 1.5 Hz, 1H), 5.26 (s, 2H), 3.05 (s, 3H), 2.76 – 2.64 (m, 1H), 1.91 – 1.13 
(m, 10H); HRMS (ESI) m/z = 293.0956 [M+Na]+, HRMS (ESI+) calculated for C12H18N2O3S: 
















Synthesis of 58. To a solution of trifluoroacetamide 47 (207 mg, 0.565 mmol, 1.0 eq) and 4 (199 
mg, 0.735 mmol, 1.3 eq) in acetonitrile (4.4 mL) was added K2CO3 (313 mg, 2.26 mmol, 4.0 eq) 
and NaI (32 mg, 0.215 mmol, 0.38 eq) under an atmosphere of argon. The suspension was heated 
to 60 °C, stirred for 14 hours, and quenched with water. The reaction mixture was extracted with 
ethyl acetate, washed with brine, dried over anhydrous Na2SO4, and solvent was condensed in 
vacuo. Purification by flash chromatography (1:1 hexanes/ethyl acetate) gave the product 58 
(296 mg, 97% yield) as a clear oil. 1H NMR (300 MHz, Chloroform-d) δ 8.44 (d, J = 1.5 Hz, 
1H), 8.35 (d, J = 1.5 Hz, 1H), 7.41 – 7.21 (m, 6H), 6.99 – 6.85 (m, 2H), 5.02 (s, 2H), 4.95 (s, 
2H), 3.08 (s, 3H), 2.81 (s, 3H), 2.78 – 2.65 (m, 1H), 1.97 – 1.70 (m, 5H), 1.63 – 1.20 (m, 5H); 
19F NMR (282 MHz, Chloroform-d) δ -67.03; HRMS (ESI) m/z = 563.2224 [M+Na]+, HRMS 















Synthesis of 59. To a solution of trifluoroacetamide 58 (296 mg, 0.548 mmol, 1.0 eq) in 1:1 
THF/MeOH (2.7 mL) was added K2CO3 (152 mg, 1.10 mmol, 2.0 eq) under an argon 
atmosphere. The reaction mixture was stirred for 1.5 hours at room temperature, quenched with 
Sat. NH4Cl, extracted with ethyl acetate, washed with brine, dried over anhydrous Na2SO4, and 
solvent was condensed in vacuo. This process yielded the product 59 (240 mg, 99% yield) as a 
white solid. 1H NMR (300 MHz, Chloroform-d) δ 8.48 (d, J = 1.5 Hz, 1H), 8.39 (d, J = 1.5 Hz, 
1H), 7.41 – 7.24 (m, 5H), 7.11 (d, J = 8.2 Hz, 1H), 6.28 (dd, J = 8.2, 2.1 Hz, 1H), 6.24 (d, J = 2.1 
Hz, 1H), 5.02 (s, 2H), 4.91 (s, 1H), 4.41 (s, 2H), 3.05 (s, 3H), 2.86 (s, 3H), 2.80 – 2.65 (m, 1H), 
2.01 – 1.69 (m, 5H), 1.66 – 1.21 (m, 5H); HRMS (ESI) m/z = 467.2419[M+Na]+, HRMS (ESI+) 











Synthesis of 60.  Note: Water was removed azeotropically from amine 59 with anhydrous 
toluene prior to use. To an oven-dried round-bottom flask equipped with a stir bar was added 
amine 59 (221 mg, 0.498 mmol, 1.0 eq) followed by dry THF (5.3 mL) under an atmosphere of 
argon. The solution was stirred at 0 °C for 2 minutes before MeMgBr (0.89 mL, 1.24 mmol, 2.5 
eq) was added. The solution was allowed to stir at 0 °C for 10 minutes before acid chloride 35 
(203 mg, 1.05 mmol, 2.1 eq) in dry THF (5.3 mL) was added. The solution was warmed to room 
temperature, stirred for 1 hour, quenched with water, and extracted with ethyl acetate. The ethyl 
acetate layer was washed with brine, dried over anhydrous Na2SO4, and solvent was condensed 
in vacuo. Purification by flash chromatography (100% ethyl acetate) gave the product 60 (236 
mg, 75% yield) as a clear oil. 1H NMR (300 MHz, Chloroform-d) δ 8.53 (s, 1H), 8.27 (d, J = 1.5 
Hz, 1H), 7.35 – 7.16 (m, 6H), 6.92 – 6.72 (m, 2H), 5.15 – 4.84 (m, 4H), 4.63 – 4.41 (m, 1H), 
4.04 – 3.87 (m, 1H), 3.74 – 3.60 (m, 1H), 3.06 (s, 3H), 2.81 (s, 3H), 2.75 – 2.59 (m, 1H), 2.10 – 
1.64 (m, 7H), 1.60 – 1.10 (m, 14H); HRMS (ESI) m/z = 650.8310 [M+Na]+, HRMS (ESI+) 











Synthesis of 62. To a solution of carbamate 60 (236 mg, 0.376 mmol, 1.0 eq) in DCM (4.0 mL) 
was added TFA (1.06 mL, 13.9 mmol, 37.0 eq) under an argon atmosphere. After stirring for 1.5 
hours at room temperature, solvent was condensed, giving the product 61 (241 mg, 100% yield) 
in quantitative yield. To a round-bottom flask was added 61 (241 mg, 0.376 mmol, 1.0 eq) 
followed by DCM (4.0 mL) under an atmosphere of argon. The solution was stirred at 0 °C for 2 
minutes prior to the addition of DIPEA (0.52 mL, 2.98 mmol, 8.0 eq). The solution was stirred at 
0 °C for 10 minutes then sulfonyl chloride 17 (179 mg, 0.751 mmol, 2.0 eq) in dry DCM (3.8 
mL) was added. The solution was warmed to room temperature, stirred for 1.5 hours, and 
quenched with water. The aqueous phase was extracted with ethyl acetate, and the combined 
organic extracts were washed with brine, dried over anhydrous Na2SO4, and solvent was 
condensed in vacuo. Purification by flash chromatography (5:1 hexanes/ethyl acetate to 100% 









1H NMR (300 MHz, Chloroform-d) δ 8.40 (d, J = 1.5 Hz, 1H), 8.32 (d, J = 1.5 Hz, 1H), 8.18 – 
8.07 (m, 1H), 8.07 – 7.98 (m, 1H), 7.38 – 7.20 (m, 6H), 6.85 – 6.76 (m, 2H), 5.18 – 4.70 (m, 
5H), 3.98 – 3.80 (m, 1H), 3.57 – 3.43 (m, 1H), 3.07 (s, 3H), 2.83 (s, 3H), 2.76 – 2.61 (m, 1H), 
2.13 – 1.96 (m, 1H), 1.94 – 1.13 (m, 11H); 19F NMR (282 MHz, Chloroform-d) δ -122.40 – -
124.01 (m), -129.48 – -131.06 (m); HRMS (ESI) m/z = 751.252 [M+Na]+, HRMS (ESI+) 

























Synthesis of S3I-H222. To a round-bottom flask containing a stir bar was added 62 (155 mg, 
0.213 mmol, 1.0 eq) in 1:4 ethyl acetate/methanol (8.8 mL). The mixture was exchanged with 
nitrogen gas three times before Pd/C (31 mg, 20% by weight) was added. The mixture was then 
exchanged with nitrogen gas three times before being exchanged with hydrogen gas three times 
and was then was allowed to stir at 25 °C. After 24 hours the reaction was complete, the mixture 
was flushed through a CeliteÒ plug with ethyl acetate and concentrated in vacuo. Purification via 
prep-TLC yielded the product S3I-H222 (60 mg, 44% yield) as a white solid. 1H NMR (300 
MHz, Chloroform-d) δ 10.36 (s, 1H), 8.46 (d, J = 1.5 Hz, 1H), 8.37 (d, J = 1.5 Hz, 1H), 8.22 – 
8.10 (m, 1H), 8.10 – 7.99 (m, 1H), 7.37 (d, J = 8.3 Hz, 1H), 6.84 (d, J = 2.1 Hz, 1H), 6.77 (dd, J 
= 8.3, 2.1Hz, 1H), 5.21 – 4.78 (m, 3H), 4.09 – 3.93 (m, 1H), 3.75 – 3.56 (m, 1H), 3.17 (s, 6H), 
2.81 – 2.64 (m, 1H), 2.44 – 2.27 (m, 1H), 2.07 – 1.66 (m, 6H), 1.63 – 1.19 (m, 5H); 19F NMR 
(282 MHz, Chloroform-d) δ -122.73 (ddd, J = 20.0, 7.0, 4.9 Hz), -129.78 (ddd, J = 20.0, 8.9, 1.8 
Hz); HPLC Purity = 100%; HRMS (ESI) m/z = 661.2015 [M+Na]+, HRMS (ESI+) calculated for 









Synthesis of 64. To a round-bottom flask equipped with a stir bar was added aniline 63 (0.69 
mL, 7.52 mmol, 1.0 eq) followed by DCM (25.0 mL) under an atmosphere of argon. The 
solution was cooled and stirred for 2 minutes at 0 °C before pyridine (1.33 mL, 16.5 mmol, 2.2 
eq) and TFAA (1.35 mL, 9.71 mmol, 1.3 eq) were added. The solution was warmed to room 
temperature, stirred for 1.5 hours, diluted with DCM, washed with Sat. Na2SO4, washed with 
Sat. NaHCO3, washed with 1M HCl, dried over anhydrous Na2SO4, and solvent was condensed 
in vacuo. Purification by flash chromatography (7:3 hexanes/ethyl acetate) gave the product 64 
(1.24 g, 88% yield) as a white solid. 1H NMR (300 MHz, Chloroform-d) δ 8.01 (s, 1H), 7.61 – 
7.52 (m, 2H), 7.45 – 7.35 (m, 2H), 7.30 – 7.19 (m, 1H); 19F NMR (282 MHz, Chloroform-d) δ -
75.73 (d, J = 1.3 Hz); HRMS (ESI) m/z = 190.0482 [M+H]+, HRMS (ESI+) calculated for 

















Synthesis of 65. To a round-bottom flask equipped with a stir bar was added NaI (32 mg, 0.211 
mmol, 0.2 eq), K2CO3 (292 mg, 2.11 mmol, 2.0 eq), 2,2,2-trifluoro-N-phenylacetamide 64 (200 
mg, 1.06 mmol, 1.0 eq), dry acetonitrile (13.6 mL), and 2-(chloromethyl)-5-cyclohexylpyridine 3 
(2.11 mL, 1.05 mmol, 1.0 eq) under an atmosphere of argon. The suspension was warmed to 65 
°C, and stirred for 6 hours before the second addition of 2-(chloromethyl)-5-cyclohexylpyridine 
3 (2.11 mL, 1.05 mmol, 1.0 eq). The suspension was stirred for 18 hours at 65 °C, quenched with 
water, extracted with ethyl acetate, washed with brine, dried over anhydrous Na2SO4, and solvent 
was condensed in vacuo. Purification by flash chromatography (10:1 hexanes/ethyl acetate) gave 
the product 65 (218 mg, 57% yield) as a clear oil. 1H NMR (300 MHz, Chloroform-d) δ 8.36 (d, 
J = 2.3 Hz, 1H), 7.48 (dd, J = 8.1, 2.3 Hz, 1H), 7.38 – 7.28 (m, 3H), 7.28 – 7.13 (m, 3H), 5.00 (s, 
2H), 2.59 – 2.38 (m, 1H), 1.95 – 1.66 (m, 5H), 1.55 – 1.13 (m, 5H); 19F NMR (282 MHz, 
Chloroform-d) δ -66.95; HRMS (ESI) m/z = 364.1718 [M+H]+, HRMS (ESI+) calculated for 












Synthesis of 66. To a solution of trifluoroacetamide 65 (214 mg, 0.591 mmol, 1.0 eq) in 1:1 
THF/MeOH (2.0 mL) was added K2CO3 (163 mg, 1.18 mmol, 2.0 eq) under an atmosphere of 
argon. The suspension was stirred at room temperature for 23 hours, quenched with Sat. NH4Cl, 
extracted with ethyl acetate, washed with brine, dried over anhydrous Na2SO4, and solvent was 
condensed in vacuo. Purification by flash chromatography (3:1 hexanes/ethyl acetate) gave the 
product 66 (143 mg, 91% yield). 1H NMR (300 MHz, Chloroform-d) δ 8.46 (d, J = 2.3 Hz, 1H), 
7.47 (dd, J = 8.0, 2.3 Hz, 1H), 7.31 – 7.12 (m, 3H), 6.81 – 6.60 (m, 3H), 4.79 (s, 1H), 4.43 (s, 
2H), 2.62 – 2.44 (m, 1H), 2.00 – 1.71 (m, 5H), 1.53 – 1.20 (m, 5H); HRMS (ESI) m/z = 
















Synthesis of S3I-H224. Note: Water was removed azeotropically from aniline 66 with 
anhydrous toluene prior to use. To an oven-dried round-bottom flask equipped with a stir bar was 
added aniline 66 (151 mg, 0.565 mmol, 1.0 eq) followed by dry THF (4.5 mL) under an 
atmosphere of argon. The solution was cooled to 0 °C and stirred for 2 minutes prior to the 
addition of MeMgBr (1.01 mL, 1.41 mmol, 2.5 eq). The solution was stirred for 10 minutes at 0 
°C prior to the addition of acid chloride 20 (297 mg, 0.848 mmol, 1.5 eq). The solution was 
warmed to room temperature, stirred for 1 hour, quenched with cold Sat. NH4Cl and H2O, 
extracted with ethyl acetate, washed with brine, dried over anhydrous MgSO4, and solvent was 
condensed in vacuo. Purification by flash chromatography (3:1 hexanes/ethyl acetate) gave the 
product S3I-H224 (181 mg, 53% yield). 1H NMR (300 MHz, Chloroform-d) δ 8.31 (d, J = 2.3 
Hz, 1H), 7.48 (dd, J = 8.1, 2.3 Hz, 1H), 7.40 – 7.31 (m, 3H), 7.19 (d, J = 8.1 Hz, 1H), 7.16 – 
7.08 (m, 2H), 5.08 – 4.76 (m, 3H), 4.18 – 3.95 (m, 2H), 2.59 – 2.41 (m, 1H), 2.38 – 2.20 (m, 
1H), 2.06 – 1.70 (m, 6H), 1.51 – 1.20 (m, 5H); 19F NMR (282 MHz, Chloroform-d) δ -135.44 – -
136.27 (m), -146.78 – -147.56 (m), -159.27 – -160.33 (m); HPLC Purity: 99%; HRMS (ESI) m/z 
= 602.1505 [M+Na]+, HRMS (ESI+) calculated for C28H26F5N3O3S: 579.1615, found 579.1614; 










Synthesis of 68. Note: Water was removed azeotropically from aniline 66 with anhydrous 
toluene prior to use. To an oven dried round-bottom flask equipped with a stir bar was added 
aniline 66 (157 mg, 0.588 mmol, 1.0 eq) followed by dry THF (6.3 mL). The solution was 
cooled to 0 °C and stirred for 2 minutes prior to the addition of MeMgBr (1.05 mL, 1.47 mmol, 
2.5 eq). The solution was stirred for 10 minutes prior to the addition of acid chloride 35 (271 mg, 
1.23 mmol, 2.1 eq) in dry THF (6.3 mL). The solution was warmed to room temperature, stirred 
for 1 hour, and quenched with water. Ethyl acetate was used to extract the product. The ethyl 
acetate layer was washed with brine, dried over Na2SO4, and solvent was condensed in vacuo. 
Purification by column chromatography (1:1 hexanes/ethyl acetate) gave the product 67 (172 
mg) which was used in the following reaction. To a solution of carbamate 67 (172 mg, 0.382 
mmol, 1.0 eq) in DCM (4.5 mL) was added TFA (1.1 mL, 14.4 mmol, 37.0 eq) under an 
atmosphere of argon. The solution was stirred for 1.5 hours at room temperature, quenched with 
Sat. NaHCO3, and extracted with DCM. The DCM layer was washed with brine, dried over 
anhydrous Na2SO4, and solvent was removed in vacuo. Purification by flash chromatography 








1H NMR (300 MHz, Chloroform-d) δ 8.29 (d, J = 2.3 Hz, 1H), 7.43 (dd, J = 8.0, 2.3 Hz, 1H), 
7.34 – 7.19 (m, 4H), 7.10 – 6.97 (m, 2H), 5.07 – 4.87 (m, 2H), 4.29 – 4.11 (m, 1H), 3.60 – 3.45 
(m, 1H), 3.37 – 3.20 (m, 1H), 3.05 (s, 1H), 2.52 – 2.26 (m, 2H), 2.24 – 2.09 (m, 1H), 1.89 – 1.62 
(m, 5H), 1.49 – 1.09 (m, 5H); HRMS (ESI) m/z = 350.2228 [M+H]+, HRMS (ESI+) calculated 























Synthesis of S3I-H230. To a round-bottom flask equipped with a stir bar was added amine 68 
(87 mg, 0.248 mmol, 1.0 eq), followed by DCM (5.2 mL). The solution was cooled to 0 °C and 
stirred for 2 minutes prior to the addition of DIPEA (0.22 mL, 1.24 mmol, 5.0 eq). The solution 
was stirred for an additional 10 minutes at 0 °C before sulfonyl chloride 17 (118 mg, 0.496 
mmol, 2.0 eq) was added. The solution was warmed to room temperature, stirred for 1.5 hours, 
and quenched with water. The crude product was extracted with DCM, washed with brine, dried 
over anhydrous Na2SO4, and solvent was condensed in vacuo. Purification by flash 
chromatography (2:3 ethyl acetate/hexanes) gave the product S3I-H230 (80 mg, 59% yield) as a 
white solid. 1H NMR (300 MHz, Chloroform-d) δ 8.33 (d, J = 2.3 Hz, 1H), 8.21 – 8.12 (m, 1H), 
8.05 – 7.98 (m, 1H), 7.48 (dd, J = 8.1, 2.3 Hz, 1H), 7.41 – 7.31 (m, 3H), 7.25 (d, J = 8.1 Hz, 1H), 
7.19 – 7.09 (m, 2H), 5.03 – 4.87 (m, 3H), 4.02 – 3.85 (m, 1H), 3.73 – 3.54 (m, 1H), 2.57 – 2.42 
(m, 1H), 2.42 – 2.23 (m, 1H), 1.96 – 1.63 (m, 6H), 1.50 – 1.15 (m, 5H); 19F NMR (282 MHz, 
Chloroform-d) δ -123.05 (ddd, J = 20.1, 7.0, 5.0 Hz), -129.95 (ddd, J = 20.1, 9.0, 1.8 Hz); HPLC 
Purity: 100%; HRMS (ESI) m/z = 573.1740 [M+Na]+, HRMS (ESI+) calculated for 











Synthesis of 69. To a solution of 4 (199 mg, 0.7372 mmol, 1.3 eq) in dry ACN (4.4 mL) was 
added 2,2,2-trifluoro-N-phenylacetamide 64 (107 mg, 0.5671 mmol, 1.0 eq), K2CO3 (314 mg, 
2.269 mmol, 4.0 eq), and NaI (32 mg, 0.2135 mmol, 0.38 eq) under an atmosphere of argon. The 
suspension was warmed to 60 °C, stirred for 18 hours, quenched with water, and extracted with 
ethyl acetate. The ethyl acetate layer was washed with brine, dried over anhydrous Na2SO4, and 
solvent was removed in vacuo. Purification by flash chromatography (10:1 hexanes/ethyl 
acetate) gave the product 69 (175 mg, 85% yield) as a clear oil. 1H NMR (300 MHz, 
Chloroform-d) δ 8.44 (d, J = 1.5 Hz, 1H), 8.37 (d, J = 1.5 Hz, 1H), 7.37 – 7.29 (m, 3H), 7.27 – 
7.18 (m, 2H), 4.99 (s, 2H), 2.80 – 2.58 (m, 1H), 1.98 – 1.64 (m, 5H), 1.61 – 1.14 (m, 5H); 19F 
NMR (282 MHz, Chloroform-d) δ -67.09; HRMS (ESI) m/z = 386.1466 [M+Na]+, HRMS 















Synthesis of 70. To a solution of trifluoroacetamide 69 (175 mg, 0.4805 mmol, 1.0 eq) in 1:1 
THF/MeOH (2.0 mL) was added K2CO3 (133 mg, 0.9609 mmol, 2.0 eq) under an atmosphere of 
argon. The solution was stirred for 24 hours at room temperature and quenched with Sat. NH4Cl. 
The crude product was extracted with ethyl acetate, washed with brine, dried over anhydrous 
Na2SO4, and solvent was condensed in vacuo. Purification by flash chromatography (4:1 
hexanes/ethyl acetate) gave the product 70 (113 mg, 88% yield) as a white solid. 1H NMR (300 
MHz, Chloroform-d) δ 8.53 (d, J = 1.5 Hz, 1H), 8.41 (d, J = 1.5 Hz, 1H), 7.23 – 7.12 (m, 2H), 
6.78 – 6.64 (m, 3H), 4.71 (s, 1H), 4.44 (s, 2H), 2.86 – 2.64 (m, 1H), 2.01 – 1.69 (m, 5H), 1.68 – 
1.19 (m, 5H); HRMS (ESI) m/z = 268.1810 [M+H]+, HRMS (ESI+) calculated for C17H21N3: 














Synthesis of 72. Note: Water was removed azeotropically from aniline 70 with anhydrous 
toluene prior to use. To a round-bottom flask equipped with a stir bar was added aniline 70 (113 
mg, 0.4241 mmol, 1.0 eq) followed by dry THF (4.6 mL) under an atmosphere of argon. The 
solution was cooled to 0 °C and stirred for 2 minutes before MeMgBr (0.76 mL, 1.060 mmol, 
12.5 eq) was added. The solution was stirred for an additional 10 minutes at 0 °C before acid 
chloride 35 (196 mg, 0.8906 mmol, 2.1 eq) in dry THF (4.6 mL) was added. The solution was 
warmed to room temperature, stirred for 1 hour, quenched with water, and the crude product was 
extracted with ethyl acetate. The ethyl acetate layer was washed with brine, dried over anhydrous 
Na2SO4, and solvent was condensed in vacuo. Purification by flash chromatography (2:1 
hexanes/ethyl acetate) gave the product 71 (113 mg) as a clear oil. To a solution of carbamate 71 
(105 mg, 0.2339 mmol, 1.0 eq) in DCM (2.8 mL) was added TFA (0.66 mL, 8.655 mmol, 37.0 
eq). The solution was allowed to stir at room temperature for 1.5 hours. The reaction mixture 
was quenched with Sat. NaHCO3, extracted with DCM, washed with brine, dried over Na2SO4, 
and solvent was condensed in vacuo. Purification by flash chromatography (24:1 CHCl3/MeOH) 








1H NMR (300 MHz, Chloroform-d) δ 8.47 (d, J = 1.5 Hz, 1H), 8.32 (d, J = 1.5 Hz, 1H), 7.38 – 
7.23 (m, 3H), 7.15 – 7.03 (m, 2H), 5.12 – 4.84 (m, 2H), 4.33 – 4.14 (m, 1H), 3.62 – 3.43 (m, 
1H), 3.38 – 3.25 (m, 1H), 3.21 (s, 1H), 2.75 – 2.59 (m, 1H), 2.41 – 2.27 (m, 1H), 2.24 – 2.13 (m, 
1H), 1.95 – 1.66 (m, 5H), 1.60 – 1.15 (m, 5H); HRMS (ESI) m/z = 373.1998 [M+Na]+, HRMS 



























Synthesis of S3I-H235. To a round-bottom flask equipped with a stir bar was added amine 72 
(61 mg, 0.1729 mmol, 1.0 eq) followed by DCM (3.6 mL). The solution was cooled to 0 °C and 
stirred for 2 minutes before DIPEA (0.15 mL, 0.8646 mmol, 5.0 eq) was added. The solution was 
stirred for an additional 10 minutes at 0 °C before sulfonyl chloride 17 (82 mg, 0.3458 mmol, 2.0 
eq) was added. The solution was warmed to room temperature, stirred for 1.5 hours, and 
quenched with water. The crude product was extracted with DCM, and the DCM layer was 
washed with brine, dried over anhydrous Na2SO4, and solvent was condensed in vacuo. 
Purification by flash chromatography (2:1 hexanes/ethyl acetate) gave the product S3I-H235 (75 
mg, 78% yield) as a white solid. 1H NMR (300 MHz, Chloroform-d) δ 8.46 (d, J = 1.5 Hz, 1H), 
8.37 (d, J = 1.5 Hz, 1H), 8.23 – 8.12 (m, 1H), 8.08 – 7.99 (m, 1H), 7.45 – 7.36 (m, 3H), 7.24 – 
7.16 (m, 2H), 5.19 – 4.81 (m, 3H), 4.04 – 3.88 (m, 1H), 3.72 – 3.57 (m, 1H), 2.80 – 2.63 (m, 
1H), 2.41 – 2.22 (m, 1H), 1.99 – 1.70 (m, 6H), 1.58 – 1.19 (m, 5H); 19F NMR (282 MHz, 
Chloroform-d) δ -122.82 (ddd, J = 20.0, 7.0, 4.8 Hz), -129.83 (ddd, J = 20.0, 8.8, 1.8 Hz); HPLC 
Purity = 100%; HRMS (ESI) m/z = 574.1698 [M+Na]+, HRMS (ESI+) calculated for 










Synthesis of 74. To a round-bottom flask equipped with a stir bar was added 6-bromophthalazin-
1(2H)-one 73 (2.5 g, 11.11 mmol, 1.0 eq) followed by DMF (45.0 mL) under an atmosphere of 
argon. The reaction mixture was cooled to 0 °C and stirred for 2 minutes prior to the addition of 
KHMDS (13.3 mL, 13.33 mmol, 1.2 eq). The reaction mixture was stirred for an additional 10 
minutes at 0 °C before MeI (0.90 mL, 14.44 mmol, 1.3 eq) was added. The reaction mixture was 
warmed to room temperature, stirred for 23 hours, and quenched by addition to a Sat. NH4Cl 
solution. The solids were filtered and washed with water and hexanes. This process gave the 
product 74 (2.2 g, 84% yield) as a white solid. 1H NMR (300 MHz, DMSO-d6) δ 8.50 – 8.41 (m, 
1H), 8.29 – 8.24 (m, 1H), 8.07 – 7.97 (m, 2H), 4.01 (s, 3H).; HRMS (ESI) m/z = 240.9795 


















Synthesis of 75. To a round-bottom flask equipped with a stir bar was added 6-bromo-2-
methylphthalazin-1(2H)-one 74 (2.16 g, 8.317 mmol, 1.0 eq), t-butyl carbamate (1.46 g, 12.47 
mmol, 1.5 eq), Pd(OAc)2 (93 mg, 0.4158 mmol, 0.05 eq), Xantphos (240 mg, 0.4158 mmol, .05 
eq), and Cs2CO3 (5.42 g, 16.63 mmol, 2.0 eq) under an atmosphere of argon. The solids were 
exchanged with an argon atmosphere (x 3) before dioxane (82.0 mL) was added. The suspension 
was exchanged with argon (x 3) before being stirred at 100 °C for 23 hours. The reaction mixture 
was quenched with water, and extracted with ethyl acetate and DCM. The organic layers were 
washed with brine, combined, dried over anhydrous Na2SO4, and solvent was removed in vacuo. 
Purification by recrystallization (2:1 ethyl acetate/hexanes) gave the product 75 (1.97 g, 86% 
yield) as a yellow solid. 1H NMR (300 MHz, Chloroform-d) δ 8.31 (d, J = 8.7 Hz, 1H), 8.12 – 
8.01 (m, 2H), 7.45 (dd, J = 8.7, 2.2 Hz, 1H), 7.10 (s, 1H), 3.83 (s, 3H), 1.53 (s, 9H); HRMS 















Synthesis of 76. To a round-bottom flask equipped with a stir bar was added carbamate 75 (269 
mg, 0.9765 mmol, 1.0 eq) followed by DMF (5.5 mL). The reaction mixture was cooled to 0 °C 
prior to the addition of KHMDS (1.27 mL, 1.269 mmol, 1.3 eq). The reaction mixture was stirred 
for an additional 10 minutes at 0 °C before 4 (343 mg, 1.269 mmol, 1.3 eq) in DMF (2.5 mL) 
was added. The reaction mixture was warmed to room temperature, stirred for 15.5 hours, 
quenched with Sat. NH4Cl, and extracted with ethyl acetate. The ethyl acetate layer was washed 
with brine, dried over anhydrous Na2SO4, and solvent was condensed in vacuo. Purification by 
flash chromatography (column #1: 3:1 hexanes/acetone, column #2: 5:1 hexanes/acetone) gave 
the product 76 (373 mg, 85% yield). 1H NMR (300 MHz, Chloroform-d) δ 8.52 (d, J = 1.5 Hz, 
1H), 8.40 (d, J = 1.5 Hz, 1H), 8.34 (d, J = 8.7 Hz, 1H), 8.05 (d, J = 0.7 Hz, 1H), 7.81 – 7.68 (m, 
2H), 5.02 (s, 2H), 3.81 (s, 3H), 2.82 – 2.64 (m, 1H), 2.02 – 1.70 (m, 5H), 1.65 – 1.16 (m, 14H); 












Synthesis of 77. To a solution of carbamate 76 (373 mg, 0.8290 mmol, 1.0 eq) in DCM (9.5 mL) 
was added TFA (3.7 mL, 48.08 mmol, 58.0 eq) under an atmosphere of argon. The solution was 
stirred at room temperature for 3 hours, quenched with Sat. NaHCO3, and extracted with DCM. 
The DCM layer was washed with brine, dried over anhydrous Na2SO4, and solvent was 
condensed in vacuo. This process yielded the product 77 (248 mg, 86% yield). 1H NMR (300 
MHz, Chloroform-d) δ 8.53 (d, J = 1.5 Hz, 1H), 8.42 (d, J = 1.5 Hz, 1H), 8.18 (d, J = 8.8 Hz, 
1H), 7.94 (s, 1H), 7.07 (dd, J = 8.8, 2.4 Hz, 1H), 6.65 (d, J = 2.4 Hz, 1H), 5.57 (t, J = 5.2 Hz, 
1H), 4.54 (d, J = 5.2 Hz, 2H), 3.77 (s, 3H), 2.89 – 2.60 (m, 1H), 2.05 – 1.69 (m, 5H), 1.65 – 1.18 
(m, 5H); HRMS (ESI) m/z = 372.1791 [M+Na]+, HRMS (ESI+) calculated for C20H23N5O: 


















Synthesis of S3I-H233. Note: Water was removed azeotropically from aniline 77 with 
anhydrous toluene prior to use. To a round-bottom flask equipped with a stir bar was added 
amine 77 (96 mg, 0.2747 mmol, 1.0 eq) followed by dry THF (3.1 mL) under an atmosphere of 
argon. The solution was cooled to 0 °C and stirred for 2 minutes prior to the addition of MeMgBr 
(0.25 mL, 0.3572 mmol, 1.3 eq). The solution was stirred for an additional 10 minutes at 0 °C 
before acid chloride 20 (144 mg, 0.4121 mmol, 1.5 eq) was added. The solution was warmed to 
room temperature, stirred for 2.5 hours, quenched with Sat. NH4Cl, and extracted with ethyl 
acetate. The ethyl acetate layer was washed with brine, dried over anhydrous Na2SO4, and 
solvent was condensed in vacuo. Purification by preparative TLC (1:1 hexanes/acetone) gave the 
product S3I-H233 (66 mg, 38% yield) as a white solid. 1H NMR (300 MHz, Chloroform-d) δ 
8.47 – 8.40 (m, 2H), 8.35 (s, 1H), 8.10 (s, 1H), 7.71 – 7.57 (m, 2H), 5.16 – 4.73 (m, 3H), 4.17 – 
3.93 (m, 2H), 3.84 (s, 3H), 2.80 – 2.61 (m, 1H), 2.38 – 2.19 (m, 1H), 2.04 – 1.67 (m, 6H), 1.61 – 
1.19 (m, 5H); 19F NMR (282 MHz, Chloroform-d) δ -135.77 – -136.12 (m), -146.34 – -146.65 
(m), -159.18 – -159.46 (m); HPLC Purity = 100%; HRMS (ESI) m/z = 685.1653 [M+Na]+, 











Synthesis of 79. To a round-bottom flask equipped with a stir bar was added 1-bromo-3-
(difluoromethyl)benzene 78 (0.32 mL, 2.415 mmol, 1.0 eq), Xantphos (70 mg, 0.1208 mmol, 
0.05 eq), t-butyl carbamate (339 mg, 2.898 mmol, 1.2 eq), Cs2CO3 (1.57 g, 4.830 mmol, 2.0 eq), 
and Pd(OAc)2 (27 mg, 0.1208 mmol, 0.05 eq) under an atmosphere of argon. The solids were 
exchanged with argon (x 3) before dioxane (28.0 mL) was added. The suspension was exchanged 
with argon (x 3) before being heated to 100 °C. The suspension was stirred for 18 hours at 100 
°C, quenched with Sat. NH4Cl, and the crude product was extracted with ethyl acetate. The 
organic extracts were washed with brine, dried over anhydrous Na2SO4, and solvent was 
condensed in vacuo. Purification by flash chromatography (100% hexanes to 9:1 hexanes/ethyl 
acetate) gave the product 79 (368 mg, 63% yield) as a white solid. 1H NMR (300 MHz, 
Chloroform-d) δ 7.61 (s, 1H), 7.46 – 7.30 (m, 2H), 7.23 – 7.13 (m, 1H), 6.82 – 6.39 (m, 2H), 
1.52 (s, 9H); 19F NMR (282 MHz, Chloroform-d) δ -110.81 (d, J = 56.6 Hz); HRMS (ESI) m/z = 













Synthesis of 80. To a round-bottom flask equipped with a stir bar was added carbamate 79 (100 
mg, 0.4111 mmol, 1.0 eq) followed by DMF (2.32 mL). The solution was cooled to 0 °C before 
KHMDS (0.53 mL, 0.5344 mmol, 1.3 eq) was added. The solution was stirred for an additional 
10 minutes at 0 °C before alkyl chloride 3 (1.07 mL, 0.5344 mmol, 1.3 eq) was added. The 
solution was warmed to room temperature, stirred for 24 hours, quenched with Sat. NH4Cl, and 
extracted with ethyl acetate. The ethyl acetate layer was washed with brine, dried over anhydrous 
Na2SO4, and solvent was condensed in vacuo. Purification by flash chromatography (9:1 
hexanes/ethyl acetate to 8:2 hexanes/ethyl acetate) gave the product 80 (147 mg, 86% yield). 1H 
NMR (300 MHz, Chloroform-d) δ 8.37 (d, J = 2.3 Hz, 1H), 7.53 – 7.43 (m, 2H), 7.42 – 7.29 (m, 
2H), 7.28 – 7.18 (m, 2H), 6.56 (t, J = 56.4 Hz, 1H), 4.92 (s, 2H), 2.57 – 2.42 (m, 1H), 1.91 – 
1.66 (m, 5H), 1.51 – 1.15 (m, 14H); 19F NMR (282 MHz, Chloroform-d) δ -110.92 (d, J = 56.4 
Hz); HRMS (ESI) m/z = 417.2354 [M+H]+, HRMS (ESI+) calculated for C24H30F2N2O2: 













Synthesis of 81. To a solution of carbamate 80 (147 mg, 0.3517 mmol, 1.0 eq) in DCM (4.1 mL) 
was added TFA (1.56 mL, 20.38 mmol, 58.0 eq) under an atmosphere of argon. The solution was 
stirred for 3 hours at room temperature, quenched with Sat. NaHCO3, and extracted with DCM. 
The DCM layer was washed with brine, dried over anhydrous Na2SO4, and solvent was 
condensed in vacuo. Purification by flash chromatography (2:1 hexanes/ethyl acetate) gave the 
product 81 (101 mg, 91% yield). 1H NMR (300 MHz, Chloroform-d) δ 8.44 (d, J = 2.2 Hz, 1H), 
7.47 (dd, J = 8.0, 2.2 Hz, 1H), 7.30 – 7.12 (m, 2H), 6.88 – 6.30 (m, 4H), 5.08 (s, 1H), 4.41 (s, 
2H), 2.62 – 2.44 (m, 1H), 1.96 – 1.70 (m, 5H), 1.51 – 1.16 (m, 5H); 19F NMR (282 MHz, 
Chloroform-d) δ -110.45 (d, J = 56.7 Hz); HRMS (ESI) m/z = 317.1825 [M+H]+, HRMS (ESI+) 

















Synthesis of S3I-H228. To a solution of aniline 81 (101 mg, 0.3189 mmol, 1.0 eq) in DCM (3.0 
mL) was added acid chloride 20 (122.7 mg, 0.3508 mmol, 1.1 eq) under an atmosphere of argon. 
The solution was cooled to 0 °C and stirred for 2 minutes before DMAP (42.9 mg, 0.3508 mmol, 
1.1 eq) was added. The solution was warmed to room temperature and stirred for 24 hours. The 
reaction was quenched with water, extracted with DCM, washed with brine, dried over 
anhydrous Na2SO4, and solvent was condensed in vacuo. Purification by flash chromatography 
(3:1 hexanes/ethyl acetate) gave the product S3I-H228 (159 mg, 79% yield) as a white solid. 1H 
NMR (300 MHz, Chloroform-d) δ 8.30 (d, J = 2.2 Hz, 1H), 7.53 – 7.39 (m, 3H), 7.35 – 7.12 (m, 
3H), 6.58 (t, J = 56.1 Hz, 1H), 5.01 – 4.78 (m, 3H), 4.17 – 3.92 (m, 2H), 2.57 – 2.41 (m, 1H), 
2.39 – 2.20 (m, 1H), 2.06 – 1.65 (m, 6H), 1.54 – 1.14 (m, 5H); 19F NMR (282 MHz, Chloroform-
d) δ -111.51 (m), -135.75 – -136.14 (m), -146.85 – -147.48 (m), -159.40 – -160.09 (m); HPLC 
Purity = 100%; HRMS (ESI) m/z = 652.1476 [M+Na]+, HRMS (ESI+) calculated for 









Synthesis of 82. Note: Water was removed azeotropically from aniline 81with anhydrous 
toluene prior to use. To a round-bottom flask equipped with a stir bar was added aniline 81 (199 
mg, 0.6293 mmol, 1.0 eq) followed by dry THF (6.8 mL) under an atmosphere of argon. The 
solution was cooled to 0 °C and stirred for 2 minutes before MeMgBr (1.12 mL, 1.573 mmol, 2.5 
eq) was added. The solution was stirred for an additional 10 minutes at 0 °C before acid chloride 
35 (290 mg, 1.321 mmol, 2.1 eq) in dry THF (6.8 mL) was added. The solution was warmed to 
room temperature, stirred for 1 hour, and quenched with water. The crude product was extracted 
with ethyl acetate, washed with brine, dried over anhydrous Na2SO4, and solvent was condensed 
in vacuo. Purification by flash chromatography (1:1 hexanes/ethyl acetate) gave the product 82 
(200 mg, 63% yield) as a clear oil. 1H NMR (300 MHz, Chloroform-d) δ 8.24 (d, J = 2.2 Hz, 
1H), 7.48 – 7.19 (m, 6H), 6.54 (t, J = 56.2 Hz, 1H), 5.06 – 4.77 (m, 2H), 4.56 – 4.37 (m, 1H), 
4.05 – 3.91 (m, 1H), 3.73 – 3.62 (m, 1H), 2.51 – 2.35 (m, 1H), 2.20 – 1.95 (m, 2H), 1.84 – 1.60 
(m, 5H), 1.43 – 1.10 (m, 14H); 19F NMR (282 MHz, Chloroform-d) δ -110.49 – -112.13 (m); 
HRMS (ESI) m/z = 522.2543 [M+Na]+, HRMS (ESI+) calculated for C28H35F2N3O3: 499.2646, 











Synthesis of S3I-H237. To a solution of carbamate 82 (200 mg, 0.3995 mmol, 1.0 eq) in DCM 
(4.8 mL) was added TFA (1.1 mL, 14.78 mmol, 37.0 eq). The solution was stirred at room 
temperature for 1.5 hours, quenched with Sat. NaHCO3, and extracted with DCM. The DCM 
layer was washed with brine, dried over anhydrous Na2SO4, and solvent was condensed in 
vacuo. Purification by flash chromatography (24:1 CHCl3/MeOH) gave the product 83 (100 mg). 
To a round-bottom flask equipped with a stir bar was added amine 83 (100 mg, 0.2418 mmol, 
1.0 eq) followed by DCM (5.0 mL) under an argon atmosphere. The solution was cooled to 0 °C 
and stirred for 2 minutes before DIPEA (0.21 mL, 1.209 mmol, 5.0 eq) was added. The solution 
was stirred for an additional 10 minutes at 0 °C before sulfonyl chloride 17 (115 mg, 0.4836 
mmol, 2.0 eq) was added. The solution was warmed to room temperature, stirred for 1.5 hours, 
and quenched with water. The crude product was extracted with DCM, washed with brine, dried 
over anhydrous Na2SO4, and solvent was condensed in vacuo. Purification by flash 
chromatography (3:1 to 2:1 hexanes/ethyl acetate) gave the product S3I-H237 (92 mg, 38% 









1H NMR (300 MHz, Chloroform-d) δ 8.35 (d, J = 2.2 Hz, 1H), 8.23 – 8.10 (m, 1H), 8.10 – 7.99 
(m, 1H), 7.59 – 7.43 (m, 3H), 7.41 – 7.19 (m, 3H), 6.61 (t, J = 56.1 Hz, 1H), 5.11 – 4.78 (m, 
3H), 4.09 – 3.86 (m, 1H), 3.78 – 3.49 (m, 1H), 2.66 – 2.23 (m, 2H), 2.13 – 1.62 (m, 6H), 1.54 – 
1.05 (m, 5H); 19F NMR (282 MHz, Chloroform-d) δ -111.16 – -111.63 (m), -122.57 – -123.62 
(m), -129.41 – -130.59 (m); HPLC Purity = 100%; HRMS (ESI) m/z = 623.1710 [M+Na]+, 
HRMS (ESI+) calculated for C30H28F4N4O3S: 600.1818, found 600.1819; EMSA IC50 = 2.58 ± 























Synthesis of 85. To a round-bottom flask equipped with a stir bar was added tert-butyl (3-
fluorophenyl)carbamate 84 (500 mg, 2.367 mmol, 1.0 eq) was added DMF (13.0 mL) under an 
atmosphere of argon. The solution was cooled to 0 °C and stirred for 2 minutes before the 
addition of KHMDS (3.08 mL, 3.077 mmol, 1.3 eq). The solution was stirred for an additional 
10 minutes at 0 °C before alkyl chloride 3 (6.15 mL, 3.077 mmol, 1.3 eq) was added. The 
solution was warmed to room temperature and stirred for 20 hours. The reaction mixture was 
quenched with Sat. NH4Cl, extracted with ethyl acetate, washed with brine, dried over anhydrous 
Na2SO4, and solvent was condensed in vacuo. Purification by flash chromatography (9:1 
hexanes/ethyl acetate) gave the product 85 (582 mg, 64% yield). 1H NMR (300 MHz, 
Chloroform-d) δ 8.33 (d, J = 2.2 Hz, 1H), 7.42 (dd, J = 8.1, 2.2 Hz, 1H), 7.21 – 6.97 (m, 4H), 
6.74 (m, 1H), 4.86 (s, 2H), 2.52 – 2.36 (m, 1H), 1.86 – 1.59 (m, 5H), 1.44 – 1.08 (m, 14H); 19F 
NMR (282 MHz, Chloroform-d) δ -112.29 – -112.74 (m); HRMS (ESI) m/z = 407.2109 













Synthesis of 86. To a solution of carbamate 85 (582 mg, 1.513 mmol, 1.0 eq) in DCM (17.6 mL) 
was added TFA (6.71 mL, 87.7 mmol, 58.0 eq). The solution was stirred for 3 hours at room 
temperature, quenched with Sat. NaHCO3, extracted with DCM, washed with brine, dried over 
anhydrous Na2SO4, and solvent was condensed in vacuo. Purification by flash chromatography 
(3:1 hexanes/ethyl acetate) gave the product 86 (309 mg, 72% yield). 1H NMR (300 MHz, 
Chloroform-d) δ 8.43 (d, J = 2.3 Hz, 1H), 7.49 (dd, J = 8.0, 2.3 Hz, 1H), 7.32 – 7.17 (m, 1H), 
7.16 – 7.01 (m, 1H), 6.49 – 6.28 (m, 3H), 4.94 (s, 1H), 4.39 (s, 2H), 2.64 – 2.38 (m, 1H), 1.98 – 
1.68 (m, 5H), 1.56 – 1.16 (m, 5H); 19F NMR (282 MHz, Chloroform-d) δ -112.97 (ddd, J = 11.5, 
8.8, 6.8 Hz); HRMS (ESI) m/z = 285.1766 [M+H]+, HRMS (ESI+) calculated for C18H21FN2: 

















Synthesis of S3I-H239. To a solution of aniline 86 (100 mg, 0.352 mmol, 1.0 eq) in DCM (3.3 
mL) was added acid chloride 20 (135 mg, 0.3868 mmol, 1.1 eq) under an atmosphere of argon. 
The solution was cooled to 0 °C and stirred for 2 minutes before DMAP (47 mg, 0.3868 mmol, 
1.1 eq) was added. The solution was warmed to room temperature and stirred for 24 hours. The 
reaction mixture was quenched with water, extracted with DCM, washed with brine, dried over 
anhydrous Na2SO4, and solvent condensed in vacuo. Purification by flash chromatography (3:1 
hexanes/ethyl acetate) gave the product S3I-H239 (97 mg, 46% yield) as a white solid. 1H NMR 
(300 MHz, Chloroform-d) δ 8.32 (d, J = 2.3 Hz, 1H), 7.48 (dd, J = 8.1, 2.3 Hz, 1H), 7.40 – 7.28 
(m, 1H), 7.17 (d, J = 8.1 Hz, 1H), 7.12 – 7.02 (m, 1H), 7.01 – 6.88 (m, 2H), 5.07 – 4.96 (m, 1H), 
4.91 – 4.84 (m, 2H), 4.23 – 3.94 (m, 2H), 2.62 – 2.41 (m, 1H), 2.40 – 2.19 (m, 1H), 2.12 – 1.93 
(m, 1H), 1.93 – 1.70 (m, 5H), 1.52 – 1.17 (m, 5H); 19F NMR (282 MHz, Chloroform-d) δ -
108.75 – -110.83 (m), -135.00 – -137.53 (m), -146.10 – -148.18 (m), -158.37 – -161.07 (m); 
HPLC Purity = 100%; HRMS (ESI) m/z = 620.1420 [M+Na]+, HRMS (ESI+) calculated for 











Synthesis of 87. Note: Water was removed azeotropically from aniline 86 with anhydrous 
toluene prior to use. To an oven-dried round-bottom flask equipped with a stir bar was added 
aniline 86 (100 mg, 0.3517 mmol, 1.0 eq) followed by dry THF (3.8 mL). The solution was 
cooled to 0 °C and stirred for 2 minutes before MeMgBr (0.63 mL, 0.8791 mmol, 2.5 eq) was 
added. The solution was stirred for an additional 10 minutes at 0 °C before acid chloride 35 (162 
mg, 0.7386 mmol, 2.1 eq) was added. The solution was warmed to room temperature and stirred 
for 1 hour. The reaction mixture was quenched with water, extracted with ethyl acetate, washed 
with brine, dried over anhydrous Na2SO4, and solvent was condensed in vacuo. Purification by 
flash chromatography (1:1 hexanes/ethyl acetate) followed by a 1M HCl and Sat. NaHCO3 wash 
gave the product 87 (98 mg, 60% yield) as a clear oil. 1H NMR (300 MHz, Chloroform-d) δ 8.30 
(d, J = 2.2 Hz, 1H), 7.47 (dd, J = 8.0, 2.2 Hz, 1H), 7.42 – 7.24 (m, 2H), 7.07 – 6.88 (m, 3H), 5.13 
– 4.77 (m, 2H), 4.64 – 4.47 (m, 1H), 4.13 – 3.97 (m, 1H), 3.82 – 3.65 (m, 1H), 2.55 – 2.40 (m, 
1H), 2.23 – 2.05 (m, 2H), 1.93 – 1.64 (m, 5H), 1.54 – 1.16 (m, 14H); 19F NMR (282 MHz, 
Chloroform-d) δ -110.17 – -110.60 (m); HRMS (ESI) m/z = 468.2666 [M+H]+, HRMS (ESI+) 











Synthesis of S3I-H244. To a solution of carbamate 87 (85 mg, 0.1824 mmol, 1.0 eq) in DCM 
(2.2 mL) was added TFA (0.51 mL, 6.750 mmol, 37.0 eq) under an atmosphere of argon. The 
solution was stirred at room temperature for 1.5 hours. The reaction mixture was quenched with 
Sat. NaHCO3, extracted with DCM, washed with brine, dried over anhydrous Na2SO4, and 
solvent was condensed in vacuo. Purification by flash chromatography (24:1 CHCl3/MeOH) 
gave the product 88 (52 mg). To a round-bottom flask equipped with a stir bar was added amine 
88 (52 mg, 0.1426 mmol, 1.0 eq) followed by DCM (3.0 mL) under an atmosphere of argon. The 
solution was cooled to 0 °C and stirred for 2 minutes before DIPEA (0.12 mL, 0.713 mmol, 5.0 
eq) was added. The solution was stirred for an additional 10 minutes at 0 °C before sulfonyl 
chloride 17 (68 mg, 0.2852 mmol, 2.0 eq) was added. The solution was warmed to room 
temperature and stirred for 1.5 hours. The reaction mixture was quenched with water, extracted 
with DCM, washed with brine, dried over anhydrous Na2SO4, and solvent was condensed in 
vacuo. Purification by flash chromatography (3:1 hexanes/ethyl acetate) gave the product S3I-










1H NMR (300 MHz, Chloroform-d) δ 8.35 (d, J = 2.3 Hz, 1H), 8.21 – 8.10 (m, 1H), 8.08 – 8.00 
(m, 1H), 7.49 (dd, J = 8.0, 2.3 Hz, 1H), 7.42 – 7.30 (m, 1H), 7.23 (d, J = 8.0 Hz, 1H), 7.14 – 6.90 
(m, 3H), 5.11 – 4.81 (m, 3H), 4.11 – 3.85 (m, 1H), 3.77 – 3.56 (m, 1H), 2.58 – 2.44 (m, 1H), 
2.43 – 2.24 (m, 1H), 2.09 – 1.61 (m, 6H), 1.52 – 1.10 (m, 5H); 19F NMR (282 MHz, Chloroform-
d) δ -108.76 – -110.07 (m), -122.96 (ddd, J = 19.9, 7.0, 4.9 Hz), -129.95 (ddd, J = 19.9, 8.8, 1.8 
Hz); HPLC Purity = 100%; HRMS (ESI) m/z = 591.1640 [M+Na]+, HRMS (ESI+) calculated for 























Synthesis of 89. To a round-bottom flask equipped with a stir bar was added tert-butyl (3-
fluorophenyl)carbamate 84 (142 mg, 0.6743 mmol, 1.0 eq) followed by DMF (3.8 mL) under an 
atmosphere of argon. The solution was cooled to 0 °C prior to the addition of KHMDS (0.88 mL, 
0.8766 mmol, 1.3 eq). The solution was stirred at 0 °C for an additional 10 minutes before 4 (237 
mg, 0.8766 mmol, 1.3 eq) in DMF (1.7 mL) was added. The solution was warmed to room 
temperature and stirred for 19 hours. The reaction mixture was quenched with water, extracted 
with ethyl acetate, washed with brine, dried over anhydrous Na2SO4, and solvent was condensed 
in vacuo. Purification by flash chromatography (9:1 hexanes/ethyl acetate) gave the product 89 
(217 mg, 83% yield). 1H NMR (300 MHz, Chloroform-d) δ 8.47 (s, 1H), 8.34 (s, 1H), 7.24 – 
7.12 (m, 1H), 7.10 – 6.98 (m, 2H), 6.87 – 6.72 (m, 1H), 4.88 (s, 2H), 2.80 – 2.59 (m, 1H), 2.00 – 
1.62 (m, 5H), 1.62 – 1.08 (m, 14H); 19F NMR (282 MHz, Chloroform-d) δ -112.10 – -112.39 
(m); HRMS (ESI) m/z = 408.2064 [M+Na]+, HRMS (ESI+) calculated for C22H28FN3O2: 













Synthesis of 90. To a solution of carbamate 89 (217 mg, 0.5619 mmol, 1.0 eq) in DCM (6.0 mL) 
was added TFA (2.5 mL, 32.67 mmol, 58.0 eq) under an atmosphere of argon. The solution was 
stirred for 3 hours at room temperature, quenched with Sat. NaHCO3, and extracted with DCM. 
The DCM layer was washed with brine, dried over anhydrous Na2SO4, and solvent was 
condensed in vacuo. Purification by flash chromatography (5:1 hexanes/ethyl acetate) gave the 
product 90 (149 mg, 93% yield). 1H NMR (300 MHz, Chloroform-d) δ 8.49 (s, 1H), 8.39 (s, 1H), 
7.14 – 6.99 (m, 1H), 6.47 – 6.27 (m, 3H), 4.89 (t, J = 5.4 Hz, 1H), 4.39 (d, J = 5.4 Hz, 2H), 2.80 
– 2.57 (m, 1H), 1.99 – 1.68 (m, 5H), 1.64 – 1.15 (m, 5H); 19F NMR (282 MHz, Chloroform-d) δ 
-112.57 (ddd, J = 11.3, 8.6, 6.7 Hz); HRMS (ESI) m/z = 286.1718 [M+H]+, HRMS (ESI+) 















Synthesis of 91. Water was removed azeotropically from aniline 90 with anhydrous toluene prior 
to use. To an oven-dried round-bottom flask equipped with a stir bar was added aniline 90 (149 
mg, 0.5253 mmol, 1.0 eq) followed by dry THF (5.7 mL) under an argon atmosphere. The 
solution was stirred at 0 °C for 2 minutes prior to the addition of MeMgBr (0.93 mL, 1.31 mmol, 
2.5 eq). The solution was stirred for an additional 10 minutes at 0 °C before acid chloride 35 
(241 mg, 1.099 mmol, 2.1 eq) in dry THF (5.7 mL) was added. The solution was warmed to 
room temperature and stirred for 1 hour. The reaction mixture was quenched with water, 
extracted with ethyl acetate, washed with brine, dried over anhydrous Na2SO4, and solvent was 
condensed in vacuo. Purification by flash chromatography (7:1 hexanes/ethyl acetate) followed 
by a 1M HCl and Sat. NaHCO3 wash gave the product 91 (111 mg, 45% yield). 1H NMR (300 
MHz, Chloroform-d) δ 8.54 (s, 1H), 8.29 (d, J = 1.1 Hz, 1H), 7.36 – 7.23 (m, 1H), 7.07 – 6.90 
(m, 3H), 5.29 – 4.64 (m, 2H), 4.61 – 4.43 (m, 1H), 4.06 – 3.92 (m, 1H), 3.76 – 3.63 (m, 1H), 
2.72 – 2.59 (m, 1H), 2.18 – 2.01 (m, 2H), 1.92 – 1.63 (m, 5H), 1.58 – 1.12 (m, 14H); 19F NMR 
(282 MHz, Chloroform-d) δ -109.68 – -110.36 (m); HRMS (ESI) m/z = 491.2433 [M+Na]+, 










Synthesis of S3I-H245. To a solution of carbamate 91 (111 mg, 0.2365 mmol, 1.0 eq) in DCM 
(2.9 mL) was added TFA (0.67 mL, 8.750 mmol, 37.0 eq) under an atmosphere of argon. The 
solution was stirred for 1.5 hours at room temperature, quenched with Sat. NaHCO3, and 
extracted with DCM. The DCM layer was washed with brine, dried over anhydrous Na2SO4, and 
solvent was condensed in vacuo. Purification by flash chromatography (24:1 CHCl3/MeOH) 
gave the product 92 (63 mg). To a round-bottom flask equipped with a stir bar was added amine 
92 (63 mg, 0.1723 mmol, 1.0 eq) followed by DCM (3.6 mL). The solution was cooled to 0 °C 
and stirred for 2 minutes prior to the addition of DIPEA (0.15 mL, 0.8615 mmol, 5.0 eq). The 
solution was stirred for an additional 10 minutes at 0 °C before sulfonyl chloride 17 (82 mg, 
0.3447 mmol, 2.0 eq) was added. The solution was warmed to room temperature and stirred for 
1.5 hours. The reaction was quenched with water, extracted with DCM, washed with brine, dried 
over anhydrous Na2SO4, and solvent was condensed in vacuo. Purification by flash 
chromatography (3:1 hexanes/ethyl acetate) gave the product S3I-H245 (43 mg, 32% yield over 









1H NMR (300 MHz, Chloroform-d) δ 8.46 (s, 1H), 8.37 (s, 1H), 8.20 – 8.09 (m, 1H), 8.07 – 7.99 
(m, 1H), 7.47 – 7.32 (m, 1H), 7.19 – 6.94 (m, 3H), 5.22 – 4.77 (m, 3H), 4.12 – 3.87 (m, 1H), 
3.76 – 3.54 (m, 1H), 2.83 – 2.60 (m, 1H), 2.44 – 2.22 (m, 1H), 2.03 – 1.66 (m, 6H), 1.66 – 1.14 
(m, 5H); 19F NMR (282 MHz, Chloroform-d) δ -108.78 – -109.32 (m), -122.84 (ddd, J = 20.0, 
7.1, 4.9 Hz), -129.87 (ddd, J = 20.0, 9.0, 1.8 Hz); HPLC Purity = 95%; HRMS (ESI) m/z = 
592.1603 [M+Na]+, HRMS (ESI+) calculated for C28H26F3N5O3S: 569.1709, found 569.1710; 
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